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CHAPTER I 
INTRODUCTION 
Epilepsy 
Epilepsy is a common neurological disease characterized by an enduring 
predisposition to generate epileptic seizures, as determined by the occurrence of: 
1) two or more unprovoked seizures separated by at least 24 hours, 2) one 
unprovoked seizure with a probability of recurrence greater than 60%, or 3) the 
diagnosis of an epilepsy syndrome [1, 2]. Representing an estimated 0.5% of the 
global disease burden and 1% of days lost due to ill health, epilepsy affects over 
50 million people, and is the fourth most common neurological disease in the 
United States behind migraine, stroke, and Alzheimer’s disease [3-8]. With a 3% 
lifetime incidence, an estimated 1 in 26 people will develop epilepsy, costing the 
U.S. economy approximately 12.5 billion dollars annually [5, 9-13].   
In addition to seizures, there are a number of comorbidities associated 
with epilepsy including: depression, anxiety, and other psychiatric disorders; 
hyperlipidemia; hypertension; asthma; and psychosocial problems such as poor 
academic performance, increased drug abuse, and difficulties obtaining and 
maintaining employment [14-16]. People with epilepsy have an increased risk of 
premature mortality, either as a direct consequence of epilepsy (e.g. status 
epilepticus), sudden unexpected death in epilepsy (SUDEP), seizure related 
accidents, or as a result of epilepsy-associated comorbidities [5, 17-19]. In 
resource-poor countries, as many as 90% of people with epilepsy do not receive 
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adequate treatment, and in developed countries, approximately 30% of patients 
do not achieve remission of seizures despite access to current therapies [9, 16, 
20].  
Epilepsy is a spectrum disease encompassing more than 30 different 
syndromes, which range in severity from relatively mild to catastrophic and may 
be classified according to: seizure type(s); age of onset; progressive nature; 
electroencephalogram (EEG) patterns; associated interictal signs and symptoms; 
pathophysiologic mechanisms, anatomical substrates, etiological categories; or 
genetic basis [21-23]. On the mild end of the spectrum are syndromes like benign 
familial neonatal-infantile seizures (BFNIS), which is characterized by afebrile 
seizures that spontaneously remit within the first year of life without neurological 
sequelae (OMIM 607745). On the other end of the spectrum are the epileptic 
encephalopathies in which epileptic activity begins early in life, results in severe 
neurological and cognitive impairment, and is generally refractory to standard 
antiepileptic drugs [22, 24-27]. These include: early myoclonic encephalopathy, 
Ohtahara syndrome, West syndrome, Dravet syndrome (DS), myoclonic status in 
nonprogressive encephalopathies, Lennox-Gastaut syndrome, Landau-Kleffner 
syndrome, and epilepsy with continuous spike-waves during slow-wave sleep 
[28].  
Epilepsy is a multifactorial disease, the underlying causes of which can be 
broadly defined as either structural/metabolic (e.g. stroke, trauma, cortical 
malformations, infection, and disorders like tuberous sclerosis, which are 
associated with an increased risk of epilepsy) or genetic [26]. With numerous 
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epidemiological studies in twins and family pedigrees offering compelling 
evidence for epilepsy heritability and the discovery of some of the genes involved 
in monogenic epilepsy syndromes, the majority of epilepsy cases are now 
considered to be genetic in origin [29-44]. Although only 1 to 2% of genetic 
epilepsies are believed to be monogenic, the discovery of many of the genes 
involved in monogenic epilepsy syndromes over the last two decades has greatly 
improved our understanding of the molecular pathogenesis of epilepsy [35]. Most 
of these genes encode components of neuronal signaling, including nicotinic 
acetylcholine and gamma-aminobutyric acid (GABA) receptors, chloride 
channels, and of particular importance, voltage-gated sodium and potassium 
channels [35, 45-48].  
Voltage-Gated Sodium Channels 
Voltage-gated sodium channels contribute to neuronal excitability by 
initiating and propagating action potentials [49]. Upon membrane depolarization, 
a conformational change occurs in the channel via the movement of charged 
residues in the voltage-sensing domain. This activates the channel and allows 
sodium ions to enter the neuron through the channel pore, further depolarizing 
the membrane and activating additional sodium channels. The simultaneous 
activation of multiple sodium channels produces the rising phase of an action 
potential. Sodium channel α subunits are composed of four homologous domains 
(I-IV), each consisting of six α-helical transmembrane segments (S1-S6) flanked 
by cytoplasmic amino and carboxy-termini [50]. The first four transmembrane 
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segments (S1-S4) comprise the voltage-sensing domain, the main component of 
which is a stretch of hydrophobic and basic residues in S4 that provide the 
membrane voltage-sensing mechanism [51]. The S5 and S6 segments form the 
pore domain through which sodium passes. Within the pore domain, located in 
the membrane-reentrant pore loop between S5 and S6, is a selectivity filter that 
contains two conserved amino acid motifs, which are critical for sodium 
selectivity [49, 52].  
There are four sodium channel α subunits expressed throughout the 
central nervous system. Nav1.1 channels (encoded by SCN1A) and Nav1.3 
channels (encoded by SCN3A) are primarily localized to neuronal cell bodies 
[53]. Nav1.2 channels (encoded by SCN2A) are expressed on dendrites and 
unmyelinated or pre-myelinated axons, and Nav1.6 channels (encoded by 
SCN8A) are located on axon initial segments, dendrites, and nodes of Ranvier 
[53, 54].  
Voltage-Gated Sodium Channels and Epilepsy 
Epilepsy-associated mutations have been reported in each of the neuronal 
voltage-gated sodium channel α subunits. In the interest of brevity, only SCN1A 
and SCN2A, the two channels associated with the most mutations, will be 
highlighted here. Mutations in the SCN1A gene, encoding the α subunit of the 
type I voltage-gated sodium channel (Nav1.1), are the leading cause of 
monogenic epilepsies with nearly 900 mutations identified in patients with various 
epilepsy syndromes including febrile seizures, genetic (generalized) epilepsy with 
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febrile seizures plus (GEFS+), Lennox-Gastaut and DS or its variants (intractable 
childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), and severe 
myoclonic epilepsy, borderline) [35, 42-44, 55-60]. SCN1A mutations are 
extremely heterogenous, with mutations distributed over nearly every part of the 
channel and very few sites of re-mutations observed [44, 61]. Over 650 distinct, 
heterozygous SCN1A mutations have been identified in patients with DS, 
accounting for approximately 85% of the patients tested [55]. Over 90% of these 
mutations arise de novo, and approximately half are nonsense or frameshift 
mutations that result in protein truncation, demonstrating the haploinsufficiency of 
SCN1A [44, 59].  
Heterozygous Scn1aK0/+ knockout mouse models exhibit phenotypes with 
features similar to those observed in DS patients, including frequent, 
spontaneous seizures, cognitive and motor deficits, and premature lethality [62-
65]. Hippocampal GABAergic interneurons from Scn1aK0/+ postnatal day 13-14 
mice exhibit reduced sodium current density, while hippocampal pyramidal 
neuron current density remains unchanged from wild-type [62]. However, at 
postnatal day 21-24 there is enhanced sodium current density in hippocampal 
pyramidal neurons as well as suppressed sodium current density from 
GABAergic interneurons [66]. This enhancement is accompanied by more 
frequent firing of spontaneous and evoked action potentials and conincides with 
the time at which Scn1aK0/+ mortality peaks [66]. Thus, it appears that a reduction 
in GABAergic inhibition and a secondary intensification of neuronal excitability 
contribute to the Scn1aK0/+ phenotype. 
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Over 20 missense mutations have been identified in the paralogous 
sodium channel gene SCN2A in patients with BFNIS and GEFS+ [55]. More 
recently, de novo missense SCN2A mutations were identified in patients with 
epileptic encephalopathies including DS and Ohtahara syndrome, and one 
nonsense mutation with an apparent dominant negative effect was reported in a 
patient with intractable epilepsy and severe mental decline [55, 64, 67-70]. A 
common mechanism by which SCN2A contributes to epilepsy susceptibility 
remains elusive as both gain-of-function and loss-of-function mutations can result 
in epilepsy, but it appears that the clinical severity of the phenotype is correlated 
with the extent to which the biophysical function of the channel is disrupted by 
the mutation [55].  
Scn2aQ54 (Q54) transgenic mice, with pan-neuronal expression of a 
mutant rat brain IIA sodium channel (Nav1.2), exhibit a progressive epilepsy 
phenotype with seizures, which originate in the hippocampus, beginning at two 
months of age. These seizures are accompanied by behavioral arrest, 
stereotyped repetitive behaviors, hippocampal cell loss and gliosis, mossy fiber 
sprouting, and a reduced lifespan [71]. Hippocampal slice recordings from Q54 
mice demonstrate network hyperexcitability [72]. The phenotype results from a 
gain-of-function mutation (GAL879-881QQQ) in the S4-S5 linker region in the 
second domain of the channel, resulting in slowed inactivation and increased 
persistent sodium current in neurons isolated from the hippocampus of 
presymptomatic Q54 mice, implicating increased persistent sodium current as a 
possible mechanism for neuronal hyperexcitability [71].    
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Voltage-Gated Potassium Channels 
Voltage-gated potassium channels, the most diverse group of ion 
channels, modulate neuronal excitability by regulating the resting membrane 
potential and controlling the shape, duration, and frequency of action potentials 
[73]. Although the expression patterns and functions of voltage-gated potassium 
channels vary greatly, most are generally closed at neuronal resting membrane 
potentials and open after membrane depolarization, allowing potassium to leave 
the cell and thus repolarizing the membrane. Four α-subunits, each analogous in 
structure to a single domain of a voltage-gated sodium channel, combine to form 
a functional potassium channel [73-76]. Similar to a voltage-gated sodium 
channel, the potassium channel selectivity filter also contains highly conserved 
amino acids that are critical for ion selectivity [77, 78]. Glycine-tyrosine-glycine 
(GYG) residues line the narrowest part of the potassium (K+)-conducting pore 
and contribute precisely spaced backbone carbonyls which help to coordinate 
dehydrated K+ ions as they move through the channel [79-81]. Alteration of these 
residues disrupts the pore and results in altered ion selectivity [79, 82-84].  
Potassium channel α-subunits are divided into nine subfamilies (Kv1 
through Kv9) according to sequence similarity [73]. Subunits comprising the Kv1 
through Kv4 subfamilies form functional homotetramers when heterologously 
expressed, and subunits within the same subfamily can also heterotetramerize to 
form channels with current properties distinct from the parent subunits [85-94]. 
Members of the Kv5 through Kv9 subfamilies generally do not function as 
homotetramers [85-87]. Rather, they act as modulatory subunits, binding to Kv2 
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subfamily members and imparting distinct functional properties by altering current 
density, kinetic, and/or other gating properties [95-101].  
Voltage-Gated Potassium Channels and Epilepsy 
Mutations associated with epilepsy have been identified in several genes 
encoding voltage-gated potassium channel subunits or accessory subunits 
including: KCNA1 (Kv1.1), KCNAB2 (Kvβ2), KCND2 (Kv4.2), KCNV2 (Kv8.2), 
KCNQ2 (Kv7.2), KCNQ3 (Kv7.3), and KCNH2 (Kv11.2) [38-40, 102-121].   
KCNQ2 and KCNQ3, encoding the M-type potassium channel subunits Kv7.2 
and Kv7.3, were among the first genes identified in association with genetic 
epilepsies. M-current, present in many parts of the brain, contributes to the 
polarization of neuronal resting membrane potentials, preventing repetitive firing 
and mediating spike-frequency adaption [122, 123]. Mutations in these genes, 
most of which result in loss-of-function or dominant-negative effects on channel 
function, have been associated with both benign familial neonatal convulsions 
(BFNC) and epileptic encephalopathy [39, 40, 124-126]. As with SCN2A, the 
clinical severity of the phenotype seems to be correlated with the degree to which 
the mutation impairs channel function, with a 25% reduction in M-current 
predicted to be sufficient to cause epilepsy [127, 128].  
Consistent with the idea that reduction of Kv7.2/Kv7.3-mediated M-current 
results in hyperexcitability, heterozygous Kcnq2 knock-out mice (Kcnq2+/-) exhibit 
hypersensitivity to pentylenetetrazole induced seizures [129]. Additionally, knock-
in mice heterozygous for BFNC mutations (Kcnq2A306T/+ and Kcnq3G311V/+) exhibit 
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reduced thresholds to electrically induced seizures, and mice homozygous for 
these mutations have spontaneous generalized tonic-clonic seizures concurrent 
with reduced M-current from CA1 hippocampal pyramidal neurons [130]. 
Moreover, the anti-epileptic drug ezogabine (retigabine) enhances M-current by 
stabilizing the open conformation of Kv7.2/Kv7.3 channels, and a structural 
analogue of retigabine, flupirtine, has been shown to prevent kainite-induced 
status epilepticus and fluorothyl-induced seizures in rats [131-134]. 
Genetic and Phenotypic Heterogeneity In Monogenic Epilepsies 
As evidenced by the previous discussion of voltage-gated sodium and 
potassium channel mutations associated with epilepsy, monogenic epilepsy 
syndromes exhibit a considerable degree of phenotypic and genetic 
heterogeneity, with different mutations in the same gene resulting in different 
epilepsy syndromes (e.g. SCN1A, SCN2A, KCNQ2) and mutations in different 
genes resulting in similar epilepsy syndromes (e.g. SCN1A and SCN2A 
mutations resulting in GEFS+) [41, 55, 135-139]. Furthermore, incomplete 
penetrance and variable expressivity are commonly observed in families with 
inherited epilepsy mutations [35].  For example, among thirteen family members 
with an inherited GEFS+ mutation (SCN1AR1648H) one had only febrile seizures; 
seven had febrile seizures and epilepsy; four had epilepsy without febrile 
seizures; and one was asymptomatic [42, 136]. Moreover, among the individuals 
who developed epilepsy, the age of onset of the first epileptic seizure varied from 
3-60 years [42, 136].  
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Analogous to the variable expressivity observed in humans, the 
phenotypes of mouse models of epilepsy are often dependent on the genetic 
background of the mice. The heterozygous Scn1aKO/+ knockout mouse model of 
DS exhibits no overt phenotype on the 129S6/SvEvTac (129) background, but 
when bred with the C57BL/6J (B6) strain, the resulting F1 generation exhibits a 
severe epilepsy phenotype and premature lethality [66]. The Q54 phenotype is 
also dependent upon the strain background of the mice with congenic B6 mice 
carrying the Q54 transgene (C57BL/6J.Q54) exhibiting delayed onset of 
seizures, decreased incidence of spontaneous seizures, and increased lifespan 
relative to [C57BL/6J x SJL/J]F1.Q54 mice [140].  
Genetic Modifiers 
The genetic and phenotypic heterogeneity observed among the 
monogenic epilepsies in humans and the strain-dependent phenotypes observed 
among genetic mouse models of epilepsy strongly suggest that genetic modifiers 
influence epilepsy phenotypes. Genetic modifiers are non-allelic genes or loci 
that segregate independently from the primary mutation and alter its phenotypic 
expression, influencing penetrance, progression, age of onset, and/or clinical 
severity of the mutant phenotype [141]. Genetic modifier loci have been mapped 
in a number of neurological diseases including: cystic fibrosis, amyotrophic 
lateral sclerosis, Alzheimer disease, Huntington disease, tuberous sclerosis, 
Hirschsprung disease, and epilepsy [117, 142-148]. The identification of genetic 
modifiers provides insight into the complex pathophysiology of heritable diseases 
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and can suggest novel targets for the development of rational therapeutic 
strategies.  
Identifying modifier genes in humans can be arduous. Unbiased genetic 
mapping approaches require large, well-characterized cohorts of affected 
individuals, and candidate gene approaches are limited by a priori knowledge. 
Genetic mouse models provide a tractable alternative to human-based 
strategies. The strain-dependent phenotypes of genetic mouse models 
recapitulate the heterogeneity observed in humans and can be exploited to 
identify genetic modifiers by crossing mutations onto different inbred strain 
backgrounds and using conventional genetic mapping approaches to isolate the 
loci responsible for the phenotype modification.  
Our lab used this approach to identify two loci, designated Moe 1 (Modifier 
of Epilepsy 1) and Moe2 (Modifier of Epilepsy 2) on Chromosomes 11 and 19, 
respectively, that contribute to the strain-dependent phenotype of Q54 transgenic 
mice [140]. We further refined the Moe2 interval on Chromosome 19 to a 5-Mb 
region using interval-specific congenic strains carrying various SJL/J (SJL)-
derived segments of the Moe2 region on the B6 background. Sequencing of 
brain-expressed positional candidate genes within the 5-Mb region revealed 
three synonymous and two non-synonymous variants (Q252R and R208H) that 
differed between the B6 and SJL strains in the voltage-gated potassium channel 
subunit subfamily V, member 2 (Kcnv2) [149].  
 12 
KCNV2 (Kv8.2) and KCNB1 (Kv2.1) 
Kv2.1 channels (encoded by KCNB1) are widely expressed throughout the 
brain in both projection and interneurons of the hippocampus and cortex where 
they are the main contributors to delayed rectifier potassium current [150-155]. 
This current contributes to membrane repolarization after action potential firing 
and is an important determinant of intrinsic neuronal excitability [150, 155, 156]. 
Kv2.1 channels dynamically regulate neuronal excitability via delayed rectifier 
potassium current in response to neuronal activity. Typically localized to large 
clusters on somata and proximal dendrites of pyramidal neurons, under 
conditions of repetitive stimulation, Kv2.1 channels undergo a calcineurin-
mediated dephosphorylation and assume a more uniform distribution. This 
change in distribution is accompanied by a hyperpolarizing shift in voltage 
dependence of activation and inactivation gating properties resulting in a 
suppression of neuronal firing [150, 156, 157]. Thus, Kv2.1 channels are 
important regulators of neuronal excitability.  
Kcnv2 encodes Kv8.2, a modulatory voltage-gated potassium channel 
subunit. When expressed alone in heterologous expression systems, Kv8.2 
subunits are retained in the endoplasmic reticulum, and are therefore non-
functional as homotetramers [85]. Kv2.1 and Kv8.2 have similar expression 
patterns in the cortex, where they are expressed predominately in Layers 2/3 and 
5, and in the hippocampus, where they are found in the principal excitatory 
neurons of the pyramidal cell layers and dentate gyrus [158-162]. Direct 
interaction between Kv8.2 and Kv2.1 has been demonstrated in mammalian cell 
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lines and in Xenopus oocytes, resulting in suppression of Kv2.1-mediated 
delayed rectifier potassium current and altered kinetic properties [85, 86, 117]. 
Suppression of Kv2.1-mediated delayed rectifier potassium current by Kv8.2 
could predispose neurons to increased excitability by impairing membrane 
repolarization, especially under conditions of repetitive firing. 
Summary 
Epilepsy is a common neurological spectrum disease that places a 
tremendous burden not only on affected individuals and their families but also on 
society as a whole. Genetic factors contribute to the majority of epilepsy cases, 
and most of the genes associated with monogenic epilepsy syndromes encode 
components of neuronal signaling, including voltage-gated sodium and 
potassium channels, the coordinated activities of which are critical in determining 
neuronal excitability. Genetic and phenotypic heterogeneity are frequently 
associated with monogenic epilepsy syndromes, and strain-dependent 
phenotypes are common among genetic mouse models of epilepsy, suggesting 
that genetic modifiers influence epilepsy phenotypes. Identifying genetic 
modifiers that contribute to epilepsy susceptibility can enrich our understanding 
of epilepsy etiology, and may reveal novel therapeutic strategies. Mouse models 
of epilepsy provide a system in which genetic modifiers can be systematically 
identified. 
Using the Q54 transgenic mouse model of epilepsy, our lab previously 
identified Kcnv2 as a candidate modifier gene. Chapter II, modified from Jorge et 
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al., 2011, describes the validation of Kcnv2 as a genetic modifier of epilepsy in 
mice and the functional characterization of two KCNV2 variants identified in 
pediatric epilepsy patients.  
The data described in Chapter II suggested that Kcnv2 is a quantitative 
modifier of epilepsy in mice, with increased Kcnv2 expression correlated with a 
more severe Q54 phenotype. We hypothesize that regulatory sequence variation 
in the Kcnv2 promoter and/or 3’ untranslated region (UTR) influences seizure 
susceptibility by altering steady-state expression levels. Chapter III describes the 
characterization of the Kcnv2 promoter and 3’ UTR regions. These studies 
provide the foundation for future studies to determine the effect of sequence 
variation in these regions on Kcnv2 expression. 
The identification of Kcnv2 as a genetic modifier of epilepsy implicated 
alteration of delayed rectifier potassium current as a potential mechanism for 
increased neuronal excitability. As the primary mediator of delayed rectifier 
potassium current, we hypothesized that genetic variation in KCNB1 (Kv2.1) may 
also contribute to epilepsy risk. Chapter IV, modified from Torkamani et al., 2014, 
describes the functional characterization of three KCNB1 mutations that were 
identified in three unrelated pediatric epilepsy patients with epileptic 
encephalopathy by whole-exome sequencing. Chapter V is a summary of the 
conclusions and implications of the studies described in Chapters II-IV followed 
by suggestions for future directions.  
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CHAPTER II  
VOLTAGE-GATED POTASSIUM CHANNEL KCNV2 (KV 8.2) CONTRIBUTES 
TO EPILEPSY SUSCEPTIBILITY∗ 
Introduction 
Epilepsy is a common neurological disorder affecting approximately 1% of 
the population worldwide [4, 163, 164]. Over the last 15 years, a number of 
genes responsible for monogenic epilepsy have been identified. Most of the 
responsible genes are components of neuronal signaling, including voltage-gated 
ion channels [165]. Mutations in the voltage-gated sodium channel genes SCN1A 
and SCN2A are responsible for several types of human epilepsy, including 
GEFS+, DS, and BFNIS [44]. More than 700 SCN1A mutations have been 
reported to date, making this gene the most frequently identified cause of 
monogenic epilepsy. Approximately 20 SCN2A mutations have been reported in 
patients with BFNIS, GEFS+, and DS [44]. Variable expressivity is a common 
feature of monogenic epilepsy caused by ion channel mutations, suggesting that 
genetic modifiers may influence clinical severity [55]. 
Q54 transgenic mice are a model of sodium channel-dependent epilepsy. 
These mice express a gain-of-function mutation in Scn2a that results in 
                                            
∗ Modified from: Jorge, B.S., et al., Voltage-gated potassium channel KCNV2 
(Kv8.2) contributes to epilepsy susceptibility. Proceedings of the National 
Academy of Sciences, 2011. 108(13): p. 5443-5448. 
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progressive epilepsy that begins with brief, spontaneous partial motor seizures 
[71]. As they age, Q54 mice exhibit more frequent partial seizures, as well as 
secondarily generalized seizures, and have a reduced lifespan. Excitatory 
hippocampal pyramidal neurons from Q54 mice display elevated persistent 
current that is predicted to increase neuronal excitability and contribute to seizure 
generation [71]. Severity of the epilepsy phenotype in Q54 is highly dependent 
on genetic background. The phenotype is less severe on the resistant strain (B6), 
with delayed seizure onset and improved survival, compared with the susceptible 
strain (SJL) [140]. We previously mapped two modifier loci that influence the 
difference in severity between these two strains: Moe1 on chromosome 11 and 
Moe2 on chromosome 19 [140]. Previous linkage analysis identified Kcnv2 as a 
strong candidate for the Moe2 locus [149]. Kcnv2 encodes the voltage-gated 
potassium channel Kv8.2, which is a silent subunit as a homotetramer. Kv8.2 can 
form functional heterotetramers with Kv2 subunits and influence membrane 
translocation and channel properties [85, 86]. Members of the Kv2 family are 
expressed in the nervous system and underlie the neuronal delayed rectifier K+ 
current, which is important for limiting membrane excitability, particularly under 
conditions of repetitive stimulation [150]. In the hippocampus, which is a region of 
particular importance for seizure generation, Kv2.1 is the major contributor to the 
delayed rectifier potassium current [166] and colocalizes with Kv8.2 in 
hippocampal pyramidal neurons [167]. 
To test the contribution of strain-dependent variation in Kcnv2 to epilepsy 
susceptibility, we characterized the functional effects of previously identified 
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nonsynonymous coding variants and compared transcript levels between strains. 
We also evaluated the in vivo effect of Kcnv2 variants in transgenic mice. To 
determine whether the human ortholog contributes to human epilepsy, we 
screened epilepsy patients for genetic variation in KCNV2. Our studies 
demonstrate Kcnv2 transgene-mediated transfer of seizure susceptibility in mice, 
as well as human variants that alter delayed rectifier K+ currents. These results 
implicate KCNV2 as an epilepsy gene in mice and humans. 
Materials and Methods 
Transgene Constructs 
The Kcnv2 open reading frame was amplified by RT-PCR from mouse 
brain RNA and cloned into a neuron specific enolase (NSE) transgene 
expression construct as previously described [71]. The transgene contains the 4-
kb promoter fragment from the rat NSE gene that includes 2.8 kb of flanking 
sequence, exon 1, intron 1, and 6 bp of noncoding sequence from exon 2, and 
the SV40 late polyadenylation sequence [168]. Constructs were confirmed by 
sequencing before transgene microinjection. 
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Animals 
All experimental protocols were approved by the Vanderbilt University 
Institutional Animal Care and Use Committee, in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. Q54 
transgenic mice [Tg(Eno2-Scn2a1*)Q54Mm] congenic on the B6 background 
(B6.Q54) were established as described and are maintained by continued 
backcrossing of hemizygous transgenic males to B6 females. Transgenic mice 
carrying a B6 Kcnv2 cDNA [Tg(Kcnv2B)1Jak] or SJL Kcnv2 cDNA 
[Tg(Kcnv2S)1Jak] were generated by pronuclear injection into B6 fertilized 
oocytes in the University of Michigan Transgenic Animal Core or the Vanderbilt 
University Transgenic Mouse/ESC Shared Resource. Transgenic founders were 
identified by PCR genotyping as described below. Each founder was crossed to 
strain B6 to generate an independent transgenic line, and lines were maintained 
by continued backcrossing of transgenic hemizygotes to B6. We generated two 
lines that carry the SJL Kcnv2 cDNA transgene (Kcnv2-S1, S2) and two lines that 
carry the B6 cDNA transgene (Kcnv2-B1, B2). We crossed B6.Kcnv2 transgenic 
mice to B6.Q54 mice to generate double-transgenic mice and single-transgenic 
littermate controls for experiments. Offspring of all genotypes were obtained at 
the expected Mendelian ratios. 
Genotyping 
Genotyping of Q54 mice was performed as previously described [140]. 
Kcnv2 transgenics were identified by PCR genotyping of genomic DNA using 
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primers located in intron 1 of NSE and in the Kcnv2 cDNA. These primers amplify 
a 935-bp band from the Kcnv2 cDNA transgene. 
Phenotyping 
Mice were tail biopsied on postnatal day 14 and genotyped. We used the 
same phenotyping paradigm that was used for mapping of the Moe2 locus [140, 
149]. Briefly, Q54;Kcnv2 double-transgenic mice and single-transgenic 
littermates were observed for visible seizures during 30-min observation periods 
at 3, 4.5, and 6 wk of age. Mice were transferred to a clean observation cage 
[7.75 in (width) × 12 in (depth) × 6.5 in (height)] just before the observation 
session. All observations occurred between 1300 hours and 1600 hours. 
Videotaped observation sessions were analyzed offline by a blinded observer 
using Observer XT behavioral coding software (Noldus). Assessment of visible 
partial motor seizures was based on prior extensive video-EEG monitoring that 
demonstrated coincident stereotyped behavioral and EEG abnormalities [71]. 
Animals exhibiting one or more seizures during the observations were classified 
as having seizures (average frequency, three per 30 min). The proportion of mice 
with a seizure frequency of one or more per 30 min by 6 wk of age was 
compared between genotypes using Fisher's exact test (n ≥ 14 per group). 
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Quantitative RT-PCR 
For comparing relative Kcnv2 levels in strains B6 and SJL, hippocampi 
were dissected from 8-wk-old B6 and SJL mice (n = 7 per strain). For 
assessment of Kcnv2 transcript levels in transgenic mice, whole-brain RNA was 
isolated from 10- to 12-wk-old Kcnv2 transgenic mice and nontransgenic 
littermates (n = 5 per line). RNA was isolated using the RNeasy kit (Qiagen). 
Real-time RT-PCR was performed as previously described [149]. Briefly, real-
time PCR was performed in triplicate using QuantiTect SYBR Green PCR mix 
(Qiagen) on an ABI 7900HT system. All reported assays exhibited a single peak 
in dissociation analysis and no detectable signal in no-RT controls. Relative 
transcript levels were assessed using the 2−ΔΔCT method [169] with TATA binding 
protein as a reference gene (Qiagen QuantiTect Assay QT00198443). Statistical 
comparison between groups was made by the pairwise fixed reallocation 
randomization test [170]. 
Plasmids and Cell Transfection 
A full-length mouse Kv8.2 cDNA was generated by RT-PCR of mouse 
brain RNA and cloning into the pIRES2-smGFP mammalian expression vector, 
which contains the CMV promoter, an IRES-2 element, and soluble modified 
GFP (DF/HCC DNA Resource Core, EvNO00025960). A full-length mouse Kv2.1 
cDNA clone was obtained from Open Biosystems (clone ID 5363843) and cloned 
into a modified pIRES2-DsRed vector (BD Biosciences-Clontech), in which we 
substituted the fluorescent protein cDNA with that of DsRed-MST (provided by 
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Dr. Andras Nagy, University of Toronto, Toronto, Canada). A full-length human 
Kv8.2 cDNA clone was obtained from Open Biosystems (clone ID 40025518) and 
cloned into the pIRES2-smGFP vector. Mutations were introduced into Kv8.2 
using the QuikChange Site-Directed Mutagenesis system (Agilent Technologies). 
Human Kv2.1 was amplified by RT-PCR from human brain total RNA (Clontech) 
and cloned into pIRES2-DsRed-MST. All clones were sequenced in their entirety 
to confirm their identity before transfection. 
Expression of Kv8.2 and Kv2.1 constructs in CHO cells was achieved by 
transient plasmid transfection using FUGENE-6 (Roche) in which 1 µg of total 
cDNA was transfected with a mass ratio of 1:1. To study the pore-forming Kv2.1 
subunit in the absence of Kv8.2, cells were transfected with pIRES2-DsRed-
MST-Kv2.1 in combination with nonrecombinant pIRES2-smGFP vector. After 
transfection, cells were incubated for 48 h before use in electrophysiological 
experiments. 
Electrophysiology 
Whole cell patch clamp recordings were performed as previously 
described [171], except the pipette solution was modified to contain lower K+ 
concentration to improve voltage-control (modified pipette solution, in mM: K+ 
aspartate 55, N-methyl-D-glucamine 55, aspartic acid 55, CaCl2 1, Hepes 10, 
EGTA 11, MgCl2 1, and K2ATP 5, pH 7.3). Whole-cell currents were measured 
from −80 to +60 mV (in 10-mV steps) from a holding potential of −80 mV. Data 
were collected for each experimental condition from at least three transient 
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transfections and analyzed and plotted using a combination of Clampfit 
(Molecular Devices) and SigmaPlot 2000 (Systat Software). Statistical analyses 
were carried out using SigmaStat 2.03 (Systat Software), and P values are 
provided in the figures or listed in the figure legends. Statistical significance 
among two groups was determined using unpaired Student’s t test, and one-way 
ANOVA followed by Tukey post test was performed when comparing more than 
two groups. Whole-cell currents were normalized for membrane capacitance, and 
results are expressed as mean ± SEM. The number of cells used for each 
experimental condition is given in the figure legends. 
Human KCNV2 Mutation Screening 
Research was approved by the local institutional review boards. Consent 
and DNA samples were obtained from study subjects. The two coding exons of 
KCNV2 were amplified from genomic DNA, and variants were identified by CSGE 
and sequencing using previously described methods [172]. SCN1A and SCN2A 
were screened by PCR amplification and sequencing of the 26 coding exons. 
NINDS neurologically normal control panels NDPT079 and NDPT093 (Coriell 
Cell Repository) were screened for the R7K and M285R variants using custom 
Taqman assays on an ABI 7900HT system (Applied Biosystems). 
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Statistical Analysis 
Values are expressed as mean ± SEM. Comparisons of mean differences 
between groups were made by unpaired two-tailed Student t test or one-way 
ANOVA unless otherwise stated. Comparisons of proportions were made by 
Fisher's exact test. For qRT-PCR results, comparisons between groups were 
made by the pairwise fixed reallocation randomization test [170]. P < 0.05 was 
considered statistically significant. 
Results 
Functional Analysis of Kcnv2 Variants in the Mouse 
We previously identified two nonsynonymous coding variants in Kcnv2 
that differ between the resistant B6 and susceptible SJL strains and 
hypothesized that functional effects of these variants may explain the differences 
in seizure susceptibility. Strain SJL carries the Kv8.2 amino acid substitutions 
R205H and Q252R [149]. We compared the functional effects of the B6 and SJL 
isoforms of Kv8.2 on potassium currents by coexpression with mouse Kv2.1 in a 
heterologous expression system. Channel cDNAs were cotransfected into CHO 
cells, and whole-cell currents were measured in the whole-cell configuration of 
the patch clamp technique [173]. Expression of mouse Kv2.1 (mKv2.1) alone 
produced large voltage-dependent potassium currents, and coexpression with 
the B6 or SJL isoforms of Kv8.2 (B6-Kv8.2, SJL-Kv8.2) resulted in significant 
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suppression of K+ current density (mKv2.1 alone, 326.1 ± 30.8 pA/pF, n = 8; 
mKv2.1 + B6-Kv8.2, 84.5 ± 5.3 pA/pF, n = 7, P < 0.001; mKv2.1 + SJL-Kv8.2, 
157.1 ± 29.1 pA/pF, n = 7, P < 0.005) (Fig. 2.1). Coexpression of mKv2.1 with 
B6-Kv8.2 produced significantly greater suppression than SJL-Kv8.2 for voltage 
steps between 0 mV and +60 mV (Fig. 2.1). Further, B6-Kv8.2, but not SJL-
Kv8.2, had a significant effect on the kinetics of activation that was limited to a 
single test potential (0 mV) without a corresponding change in voltage 
dependence (Fig. 2.2). Neither Kv8.2 isoform differed in the magnitude of 
cumulative inactivation evoked by moderate-frequency pulse trains (Fig. 2.3), but 
SJL-Kv8.2 did evoke a greater time-dependent decay in whole-cell current (Fig. 
2.1C). However, given their colocalization in excitatory neurons, the differences 
in biophysical properties of Kv2.1/B6-Kv8.2 and Kv2.1/SJL-Kv8.2 
heterotetrameric channels do not provide a clear and compelling explanation for 
strain differences in epilepsy severity in Q54 mice. 
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Figure 2.1 Functional Consequences of Amino Acid Sequence Variants in 
Mouse Kcnv2 
(A) Averaged whole-cell current traces normalized to membrane capacitance 
recorded from CHO cells expressing mKv2.1 in combination with either B6-Kv8.2 
or SJL-Kv8.2 (n = 7 for each condition). (B) Current density–voltage relationships 
for mKv2.1 coexpressed with the two Kv8.2 isoforms. Current was measured at 
1,990 ms after start of the test pulse then normalized to membrane capacitance. 
(C) Extent of time-dependent whole-cell current decay illustrated by the ratio of 
steady-state current (measured at 1,990 ms) to instantaneous current (measured 
at 100 ms). 
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Figure 2.2 Biophysical Properties of mKv2.1 Channels Coexpressed with 
mKv8.2 Subunits 
(A) Voltage dependence of activation time constants for mKv2.1 coexpressed 
with Kv8.2 isoforms (*P < 0.05 compared with WT). Time constants were 
determined from monoexponential fits to the data. Currents recorded at voltages 
<0 mV were too small to determine time constants. Inset: Averaged current 
traces (blue, mKv2.1 + SJL-Kv8.2; black, mKv2.1 + B6-Kv8.2) recorded from 10 
to 500 ms after a test pulse to 0 mV and normalized to current amplitude 
measured at 500 ms. (B) Voltage dependence of steady-state activation. Tail- 
current amplitudes were measured at −30 mV after a 2,000-ms activating pulse 
from −60 to +60 mV. Currents were normalized to peak amplitude and fit with 
Boltzmann functions. Values for activation V1/2 were not significantly different 
between B6-Kv8.2 and SJL-Kv8.2.  
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Figure 2.3 Cumulative Inactivation of Kv2.1 Channels Coexpressed with 
Kv8.2 
Current was measured during a train of 100 depolarizing pulses to +40 mV of 40-
ms duration from a holding potential of –80 mV at a frequency of 17 Hz. Currents 
were normalized to peak current amplitude. Plotted points correspond to means 
± SEM of every fifth pulse for mouse (A) and human (B) Kv8.2 subunits 
coexpressed with mouse and human Kv2.1, respectively. Cumulative inactivation 
kinetics were estimated by monoexponential decay fit to each cell recording and 
averaged. No significant differences were observed.  
Relative Expression of Kcnv2 in Hippocampus 
Whole-brain expression of Kcnv2 does not differ between strains B6 and 
SJL [149]. We further investigated strain-dependent expression in the 
hippocampus for three reasons: first, previous EEG studies showed that seizures 
in Q54 likely originate in the hippocampus [71]; second, Kcnv2 transcripts are 
enriched in the hippocampus [167]; and, third, the biophysical differences 
described above were counterintuitive and suggested more complex physiology. 
RNA was isolated from dissected hippocampi of 8-wk-old B6 and SJL mice for 
quantitative RT-PCR (qRT-PCR) analysis. Relative Kcnv2 expression was 
assessed by the 2-ΔΔCt method normalizing to TATA binding protein using the 
same assay previously used for whole-brain analysis [169]. Strain SJL exhibited 
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threefold greater expression of hippocampal Kcnv2 transcript relative to B6 (Fig. 
2.4). The finding indicates that higher Kcnv2 expression in hippocampus 
correlates with greater epilepsy severity. 
 
Figure 2.4 Relative Hippocampal Expression of Kcnv2 
Transcript levels were measured by qRT-PCR (n = 7 per strain; *P = 0.012 
compared with B6, pairwise fixed reallocation randomization test). 
Transgenic Transfer of the Modified Phenotype 
We evaluated the in vivo modifier effects of Kcnv2 using a transgenic 
transfer approach, based on the prior observation that the modifier effect is a 
dominant trait [140]. We constructed transgenes containing the B6 or SJL Kcnv2 
coding sequence under the control of the neuron-specific enolase (NSE) 
promoter. This promoter drives pan neuronal expression in transgenic mice and 
is the same promoter that drives expression of the Q54 transgene [71, 168]. To 
determine the contribution of the Kcnv2 amino acid variants, we generated 
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transgenic lines expressing the SJL-derived Kcnv2 transgenes (Kcnv2-S1, 
Kcnv2-S2). To determine whether higher expression alone is sufficient for the 
severe phenotype, we generated lines carrying the B6-derived Kcnv2 transgenes 
(Kcnv2-B1, Kcnv2-B2). 
Transgenes were microinjected into B6 oocytes and maintained on the B6 
background, ensuring a pure genetic background for experiments. The 
transgenic lines expressed varying amounts of Kcnv2 transgene transcript as 
determined by qRT-PCR (Fig. 3A). Kv8.2 protein levels exhibited a similar trend 
in the transgenic lines, as determined by immunoblotting (Fig. 2.6). Kcnv2 
transgenic hemizygotes were crossed with B6.Q54 mice to generate double-
transgenic Kcnv2;Q54 offspring and single-transgenic littermate controls that 
were phenotyped for spontaneous seizure onset and survival. For all Kcnv2 
transgenic lines, single-transgenic mice displayed no spontaneous seizures and 
had a normal lifespan. 
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Figure 2.5 Transgenic Transfer of the Modified Phenotype in Kcnv2;Q54 
Double Transgenic Mice 
(A) Relative whole-brain expression of Kcnv2 transcript measured by qRT-PCR 
(n = 5 per genotype; *P ≤ 0.002 compared with nontransgenic, pairwise fixed 
reallocation randomization test). (B) Percentage of mice exhibiting more than 1 
seizure per 30 min by 6 wk of age (*P < 0.03 compared with B6.Q54, Fisher's 
exact test). (C) Survival of Q54 mice carrying Kcnv2 transgenes and single 
transgenic B6.Q54 littermates (dashed black line).    
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Figure 2.6 Relative Whole-brain Expression of Kv8.2 Protein in Kcnv2 
Transgenic Lines  
(A) Representative immunoblot of Kv8.2 from Kcnv2 transgenic mice and 
nontransgenic littermates (WT). Brain membrane proteins (25 µg) were isolated 
at 6 wk of age and analyzed by immunoblotting with an affinity-purified rabbit 
polyclonal antiserum generated against the immunogenic peptide 
MLKQSNERRWSLSY (ProSci Inc.). The predicted molecular weight of Kv8.2 is 
64 kDa (arrowhead). Protein loading is indicated by relative intensity of the 
nonspecific immunoreactive band at ≈80 kDa. All lanes are from the same 
exposure of a single blot. Isolation of membrane proteins and Western blotting 
was carried out as previously described (1). (B) Quantitative analysis of Kv8.2 
relative protein levels normalized to the 80-kDa band (n ≥ 3 per genotype).  
Lines Kcnv2-S2 and Kcnv2-B2, with the highest levels of transgene 
expression, generated an increased number of Kcnv2;Q54 double-transgenic 
mice with seizures by 6 wk of age (Fig. 2.5 A and B). Double-transgenic mice 
with either the Kcnv2-S2 or Kcnv2-B2 transgenes also exhibited accelerated 
mortality, with 50% mortality by 10 wk and 14 wk of age, respectively, compared 
with B6.Q54 single-transgenic mice with 50% survival at 20 wk of age (Fig. 
2.5C). Lines Kcnv2-S1 and Kcnv2-B1, with lower levels of transgene expression, 
did not influence the Q54 phenotype (Fig. 2.5). The level of Kcnv2 transgene 
expression was strongly correlated with seizure phenotype (R2 = 0.85) and 24-wk 
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survival (R2 = 0.79), whereas amino acid sequence was not correlated with 
seizure phenotype (R2 = 0.008) or survival (R2 = 0.04). Although the precise 
contribution of the amino acid variants in vivo is unclear, elevated expression of 
Kcnv2 seems to be sufficient to exacerbate the Q54 epilepsy phenotype. 
Human Kcnv2 Screening 
To determine whether KCNV2 contributes to human epilepsy, we 
screened 209 pediatric epilepsy subjects for variants in KCNV2 by exon 
amplification, conformation-sensitive gel electrophoresis (CSGE), and 
sequencing [172]. A number of known polymorphic coding SNPs were present in 
the patients, including seven synonymous SNPs and a common nonsynonymous 
SNP with a population minor allele frequency of 0.12 (Table 2.1). Additionally, we 
identified two unique nonsynonymous coding variants: R7K and M285R. These 
variants were not detected in 368 neurologically normal control chromosomes 
[National Institute of Neurological Disorders and Stroke (NINDS) Neurologically 
Normal Control Panels NDPT079, NDPT093]. Additionally, these variants are not 
present in dbSNP, nor have they been reported in resequencing projects, 
including the 1000 Genomes Project 
(http://browser.1000genomes.org/index.html) and the Baylor Ion Channel 
Sequencing Project (http://www.hgsc.bcm.tmc.edu/ionchannel-snpList.xsp). 
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Table 2.1 KCNV2 Polymorphisms Detected in Screening of Pediatric 
Epilepsy Patient Samples	   
 
The KCNV2-R7K variant was identified in a patient with febrile and afebrile 
partial seizures starting at age 2 years (Table 2.2, patient 1). The variant was 
inherited from his unaffected mother. However, there is a positive family history 
of two paternal uncles with childhood epilepsy. R7K substitutes lysine for an 
evolutionarily conserved arginine in the cytoplasmic amino terminus of the Kv8.2 
channel (Fig. 2.7A). 
Table 2.2 Clinical Features of Epilepsy Patients with Unique, 
Nonsynonymous KCNV2 Coding Variants  
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Figure 2.7 Human KCNV2 Variants Identified in Epilepsy Patients  
(A) Evolutionary conservation of arginine 7. (B) Evolutionary conservation of 
methionine 285.  
The KCNV2-M285R variant was identified in a patient with an epileptic 
encephalopathy with severely refractory epilepsy (Table 2.2, patient 2). There is 
no family history of epilepsy, and the variant was inherited from his unaffected 
mother. Methionine 285 is located at the extracellular face of transmembrane 
segment 1 and is evolutionarily invariant in homologous channels from other 
mammals, birds, and fish. (Fig. 2.7B). 
Both patients were also screened for variants in the voltage-gated sodium 
channel genes SCN1A and SCN2A. No pathogenic variants were identified 
(Table 2.3). 
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Table 2.3 SCN1A and SCN2A SNPs in Patients with KCNV2 Variants  
Functional Properties of Human KCNV2 Variants 
We determined the functional consequences of the R7K and M285R 
variants engineered in human Kv8.2 by coexpressing with human Kv2.1 in CHO 
cells. Coexpression of Kv2.1 with either R7K or M285R Kv8.2 variants resulted in 
significantly greater suppression of Kv2.1-mediated current compared with wild-
type Kv8.2 for voltage steps from 0 mV to +60 mV (Fig. 2.8 A and B). 
Furthermore, M285R, but not R7K, exhibited a significant depolarizing shift in the 
voltage dependence of steady-state activation and significantly greater time 
constants of activation (τ) measured between 0 and +30 mV (Fig. 2.8 C and D). 
Neither variant differed from wild-type in the magnitude of cumulative inactivation 
evoked by moderate-frequency pulse trains (Fig. 2.3). Thus, both variants cause 
enhanced Kv2.1 suppression consistent with reduced neuronal delayed rectifier 
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current. Furthermore, these effects are compounded by the slower kinetics and 
more depolarized voltage dependence of activation evoked by M285R. 
 
 
Figure 2.8 Functional Consequences of Human KCNV2 Variants  
(A) Averaged whole-cell current traces normalized to membrane capacitance 
recorded from CHO cells coexpressing human Kv2.1 with wild-type or mutant 
Kv8.2 (n = 7 to 8 for each condition). (B) Current density–voltage relationships 
recorded from cells coexpressing Kv2.1 with wild-type or mutant Kv8.2. Current 
was measured at 1,990 ms after start of the test pulse, then normalized to 
membrane capacitance. (C) Voltage dependence of activation time constants for 
Kv2.1 coexpressed with wild-type or mutant Kv8.2 (*P < 0.05 compared with 
WT). Time constants were determined from monoexponential fits to the data. 
Currents recorded at voltages <0 mV were too small to determine time constants. 
Inset: Averaged current traces (black, hKv8.2-WT; blue, hKv8.2-R7K; red, 
hKv8.2-M285R) recorded from 10 to 500 ms after a test pulse to 0 mV and 
normalized to current amplitude measured at 500 ms. (D) Voltage dependence of 
steady-state activation. Tail-current amplitudes were measured at −30 mV after a 
2,000-ms activating pulse from −60 to +60 mV. Currents were normalized to 
peak amplitude and fit with Boltzmann functions. Values for activation V1/2 were 
as follows: wild-type Kv8.2, 0.9 ± 1.2 mV; Kv8.2-R7K, 2.0 ± 1.6 mV (not 
significantly different from wild-type); and Kv8.2-M285R, 9.1 ± 1.1 mV (P < 0.01 
compared with wild-type Kv8.2). 
 37 
Discussion 
In the present study we demonstrate important effects of Kcnv2 variants 
on seizure susceptibility in humans and mice. In transgenic mice, increased 
expression of Kcnv2 was sufficient to exacerbate the seizure phenotype in Q54 
mice. In human epilepsy patients, we identified two unique nonsynonymous 
variants that exerted increased suppression of delayed rectifier potassium 
currents. Although both human KCNV2 variants were inherited from an 
unaffected parent, they may act as susceptibility modifiers in the affected 
patients, as do the Kcnv2 variants in the Q54 mouse model. Taken together, 
these results implicate Kcnv2 as an important genetic factor in epilepsy. 
Kcnv2 encodes the voltage-gated potassium channel subunit Kv8.2, which 
is a silent subunit when expressed as a homotetramer. However, when 
coassembled as a heterotetramer with Kv2 family members, Kv8.2 influences 
membrane translocation and biophysical properties of these channels [85, 86]. 
Kv2 channels are major contributors to delayed rectifier K+ current in 
hippocampal pyramidal neurons and act to dampen excitability during high-
frequency stimulation [151, 156, 166]. Inclusion of Kv8.2 in heteromeric channels 
results in suppression of Kv2-mediated delayed rectifier potassium currents, 
which could impair membrane repolarization and thus predispose neurons to 
increased excitability. 
Direct interaction between Kv8.2 and Kv2.1 channels has been 
demonstrated by coimmunoprecipitation in HEK293 cells [85]. The Kv8.2 and 
Kv2.1 subunits also show significant regional overlap in their central nervous 
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system expression patterns. Within the hippocampus, transcripts for both Kcnv2 
and Kcnb1, which encodes Kv2.1, are detected in the principal excitatory 
neurons of the pyramidal cell layers and the dentate gyrus [159-162, 167]. 
Similarly, both Kcnv2 and Kcnb1 are expressed in the cortex, with high levels of 
transcript in Layers 2/3 and 5 [159-162, 167]. This regional colocalization is 
consistent with an effect of Kv8.2 variants on Kv2.1 channels within cells of 
critical importance for seizure generation and propagation. 
We had initially hypothesized that the amino acid differences between the 
resistant B6 and susceptible SJL strains were responsible for the divergent 
phenotypes [149]. Functional characterization of the Kv8.2 amino acid 
differences in a heterologous expression system demonstrated that the B6 
isoform was more effective at suppressing Kv2.1-mediated currents. Because 
these channels are localized in excitatory neurons and the B6 strain is more 
resistant, this result was counterintuitive and suggested that the in vivo 
physiology is more complex. Therefore, we sought to test the relative contribution 
of expression and amino acids differences in vivo. Relative expression of Kcnv2 
in hippocampus was threefold greater in the susceptible SJL strain compared 
with B6. The Kcnv2 gene is located in a divergent haplotype block between B6 
and SJL, with a high degree of noncoding sequence variation (four SNPs/kb) that 
may influence Kcnv2 transcript levels by altering the rate of transcription or 
mRNA stability [149]. Increased transgenic expression in vivo increased the 
severity of the seizure phenotype in Q54 mice, regardless of the amino acid 
sequence of the Kcnv2 transgene. This observation supports the view that higher 
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expression of Kcnv2 in strain SJL is sufficient for increased phenotype severity. 
Increased expression of Kcnv2 would be predicted to decrease Kv2.1-mediated 
delayed rectifier potassium current, which could promote increased excitability 
under conditions of repetitive stimulation. In support of this mechanism, others 
have demonstrated that antisense knockdown of Kv2.1 in hippocampal slices 
resulted in increased CA1 pyramidal neuron excitability under conditions of high-
frequency stimulation [151]. Thus, increased expression of Kcnv2 alone could 
contribute to seizure susceptibility. 
In further support of the importance of KCNV2 in seizure pathogenesis, we 
identified unique nonsynonymous variants in two unrelated children with 
epilepsy. Functional characterization of these KCNV2 variants, R7K and M285R, 
demonstrated that these variants also enhance Kv8.2-mediated suppression of 
Kv2.1 currents. These mutations would be predicted to decrease delayed rectifier 
potassium current in neurons, resulting in increased excitability under conditions 
of repetitive stimulation. The net effects would be similar to the effects of 
elevated expression of KCNV2. Consistent with the more severe clinical 
phenotype of patient 2, M285R exhibited additional kinetic defects, including a 
+10 mV shift in the voltage dependence of activation and slower activation 
kinetics. These defects are predicted to delay channel opening, which would 
likely further impair membrane repolarization and increase excitability. These 
results implicate enhanced Kv8.2 activity as a plausible genetically encoded 
factor in epilepsy susceptibility. Loss-of-function mutations in KCNV2 identified in 
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autosomal recessive retinal cone dystrophy 3 [174-177] also implicate this 
channel as an important modulator of neuronal firing patterns. 
Clinical severity in the two patients with KCNV2 variants differs, ranging 
from relatively benign febrile and afebrile seizures in patient 1 (R7K) to severe 
epileptic encephalopathy in patient 2 (M285R). However, it is not uncommon for 
missense mutations in the same gene to result in different epilepsy types of 
varying severity. For example, missense mutations in SCN1A and SCN2A have 
been reported in patients with the benign epilepsy syndrome GEFS+, as well as 
in patients with the severe epileptic encephalopathy DS [44, 55]. Several factors 
may underlie the wide spectrum of phenotypes, including the location and nature 
of the amino acid substitution, divergent effects of the mutation on protein 
function, the genetic background of the individual, and environmental effects. 
Nonconservative substitution of arginine for methionine at the extracellular face 
of transmembrane segment 1 results in more profound biophysical defects than 
the conservative R7K substitution in the amino terminus. This difference in 
dysfunction is consistent with the difference in clinical severity. Additional 
resistance and susceptibility alleles at other loci are likely to contribute to the 
overall clinical phenotype. Although we found no evidence for interaction with 
mutant sodium channels in these patients, it is conceivable that the KCNV2 
variants interact with other loci to influence epilepsy susceptibility. Patient 1 
(R7K) has a positive family history of two paternal uncles with childhood epilepsy. 
Although the R7K variant was inherited from his unaffected mother, it is possible 
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that there was paternal inheritance of additional genetic resistance or 
susceptibility factors. 
Kcnv2 belongs to a group of potassium channel modulatory subunits that 
are electrically silent and cannot form functional homotetramers. These silent 
subunits form heterotetramers and modulate the properties of Kv2 and Kv3 
channels, increasing the functional diversity of the channel subfamilies. This is 
particularly relevant for the Kv2 subfamily with only two members, Kv2.1 and 
Kv2.2. Targeting of modulatory subunits may offer a new therapeutic approach 
for fine-tuning neuronal excitability. 
The interplay between ion channels contributes to overall neuronal 
excitability. Previous results from our laboratory and others have demonstrated 
genetic interactions between voltage-gated sodium, potassium, and calcium 
channels in mouse models of epilepsy [178-180]. The present study implicates a 
unique potassium channel subtype in epilepsy and suggests that variants in ion 
channels may act to modify the clinical phenotype in human epilepsy. This may 
have implications for molecular diagnostic testing and suggests that expanded 
ion channel screening may improve the utility of molecular testing for clinical risk 
assessment and disease management in epilepsy. 
In summary, our results implicate KCNV2 as a genetic modifier of 
epilepsy, and demonstrate that isolation of genetic modifiers in mice can lead to 
the identification of human epilepsy genes. Discovery of genes that influence 
susceptibility and disease progression will provide insight into the molecular 
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events of epileptogenesis, improve molecular diagnostic utility, and identify novel 
therapeutic targets for improved treatment of human epilepsy. 
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CHAPTER III  
IDENTIFICATION OF KCNV2 REGULATORY REGIONS IN MOUSE  
Introduction 
 
Epilepsy is the fourth most common neurological disease in the United 
States behind migraine, stroke, and Alzheimer’s disease, and it costs the U.S. 
economy approximately 12.5 billion dollars annually [6, 181]. It is a multifactorial 
disease, but the majority of cases have a genetic basis [35, 36]. Significant 
progress has been made in recent years identifying monogenic epilepsy genes. 
Most of the genes that have been identified encode voltage-gated ion channels 
or other components of neuronal signaling [44, 165].  
Mutations in voltage-gated sodium channels are the leading cause of 
monogenic epilepsies. More than 800 mutations have been reported in SCN1A 
and the paralogous sodium channel gene SCN2A [55, 182, 183], resulting in a 
variety of human epilepsy syndromes, including BFNIS, GEFS+, and DS [44].  
Variable expressivity is commonly observed among family members with 
inherited epilepsy-associated mutations [55]. This suggests that genetic modifiers 
may influence the clinical severity of monogenic epilepsies. Although monogenic 
epilepsies represent only 1 to 2% of genetic epilepsies [35], recent studies have 
shown a genetic association between monogenic epilepsy genes and epilepsy 
with more complex inheritance [184-186]. Therefore, identifying and 
characterizing modifier genes that contribute to monogenic epilepsies may 
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provide additional inroads into the etiology of more common epilepsy syndromes 
with complex inheritance. 
We previously identified Kcnv2 as a genetic modifier of the seizure 
phenotype of the Q54 transgenic mouse model, which carries a gain of function 
mutation in Scn2a (GAL879-881QQQ). Q54 mice have a progressive epilepsy 
phenotype, with focal seizures originating in the hippocampus at two months of 
age and eventually progressing to generalized tonic-clonic seizures. The 
seizures are accompanied by behavioral arrest, stereotyped repetitive behaviors, 
hippocampal cell loss and gliosis, and a reduced lifespan [71].  
Analogous to the variable expressivity observed in humans with epilepsy-
associated sodium channel mutations, the phenotype of Q54 mice varies with the 
genetic background of the mice. Q54 mice on the [B6 x SJL]F1.Q54 background 
(F1.Q54) exhibit an increased incidence of spontaneous seizures, earlier seizure 
onset, and decreased survival compared to Q54 mice on the B6 background. 
This indicates that the SJL strain contributes dominant modifier alleles that alter 
the severity of the epilepsy phenotype [140]. We performed genetic mapping and 
identified two modifier loci, Moe1 on mouse chromosome 11 and Moe2 on 
chromosome 19, that contribute to the strain-dependent phenotype variability in 
Q54 mice [140]. Subsequent studies identified the voltage-gated potassium 
channel Kcnv2 as an epilepsy modifier gene at the Moe2 locus [117, 149]. 
Kcnv2 encodes Kv8.2, a modulatory voltage-gated potassium channel 
subunit that coassembles with Kv2.1 subunits, altering membrane translocation 
and biophysical properties, with suppression of Kv2.1-mediated potassium 
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current as a net consequence [85, 86]. Kv2.1 channels, encoded by Kcnb1 are 
the main contributors to delayed rectifier K+ current in the cortex and 
hippocampus where they act to dampen excitability during high frequency 
stimulation of hippocampal pyramidal neurons [151, 156, 166]. Expression 
analyses reveal significant overlap between Kcnv2 and Kcnb1 transcripts in 
principal excitatory neurons of the pyramidal cell layers and dentate gyrus of the 
hippocampus and in layers 2/3 and 5 of the cortex [159-161, 167, 187].  
Enhanced suppression of delayed rectifier potassium currents could 
predispose neurons to hyperexcitability by impairing membrane repolarization. 
Therefore, elevated expression of Kcnv2 would be predicted to heighten 
neuronal excitability, especially under conditions of repetitive stimulation [117]. 
Consistent with this prediction, the seizure-susceptible SJL strain exhibits a 
threefold increase in hippocampal Kcnv2 expression relative to the seizure-
resistant B6 strain, and elevated Kcnv2 expression is positively correlated with 
the phenotype severity of double transgenic mouse lines expressing Q54 with 
variable amounts of the Kcnv2 transgene [117]. Hence, strain-dependent 
variability in Kcnv2 expression appears to underlie its modifier effect on the Q54 
phenotype.  
The identification of Kcnv2 as a genetic modifier of epilepsy by genetic 
mapping and candidate gene analysis suggests that regulatory sequence 
variation in or near the Kcnv2 locus contributes to differences in steady-state 
Kcnv2 expression between strains. A transcript’s steady-state expression level is 
a result of the balance between its rates of transcription and degradation. 
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Elements controlling the rate of transcription are generally found upstream of the 
transcription start site (TSS) in the promoter regions of genes, while elements 
that determine the rate of mRNA degradation are often found in the 3’ UTR.  
We hypothesize that regulatory sequence variation in the promoter and/or 
3’ UTR of Kcnv2 influences seizure susceptibility by altering steady-state 
expression levels. As a first step towards addressing our hypothesis, we sought 
to define the TSS, promoter, and 3’ UTR organization of the full-length Kcnv2 
transcript. Using 5’ RNA ligase-mediated rapid amplification of cDNA ends 
(RACE) analysis and an RNase protection assay (RPA), we identified the Kcnv2 
TSS and applied this knowledge to the generation of a 5’ deletion series of 
luciferase reporter constructs to identify the core promoter region. We also 
employed 3’ RACE analysis to define the 3’ UTR organization of Kcnv2. The 
knowledge gained from these studies will inform future experiments to elucidate 
the effects of regulatory sequence variation on Kcnv2 expression levels. Taken 
together these studies will improve our understanding of the molecular basis of 
the Kcnv2 modifier effect and advance our knowledge of the mechanisms by 
which genetic modifiers influence epilepsy. 
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Methods 
Sequencing of Kcnv2 Non-Coding Sequence 
Overlapping PCR amplicons spanning 3.3 kb upstream and 3.3 kb 
downstream of the Kcnv2 open reading frame were gel purified and Sanger 
sequenced. (The amplification/sequencing primers are listed in Table 3.1.) The 
resulting sequences were aligned to the B6 reference sequence (GRCm38) for 
comparison using Sequencher software (Gene Codes, Ann Arbor, MI, USA).  
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Table 3.1 Primer and Oligo Sequences for Sequencing, RACE, and RPA 
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5’ Rapid Amplification of cDNA Ends 
Poly(A) RNA was isolated from total RNA (extracted from B6 and SJL 
eyes or whole brain with TRIzol (Life Technologies, Grand Island, NY, USA)) 
using the PolyAtract mRNA Isolation system (Promega, Madison, WI, USA). The 
poly(A) RNA was used as a template to produce RACE-ready cDNA using the 
the GeneRacer Kit (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s protocol. Briefly, poly(A) RNA was treated with calf intestinal 
phosphatase to remove 5’ phosphates from truncated transcripts, preventing the 
subsequent ligation of an RNA Oligo. The RNA was then treated with tobacco 
acid pyrophosphatase to remove the 5’ cap structure from full-length transcripts, 
and an RNA Oligo (5’ RACE Oligo) (Table 3.1) was ligated to the 5’ end of de-
capped transcripts with T4 RNA ligase. cDNA was reverse transcribed from the 
ligation product with SuperScript III reverse transcriptase  and random hexamers 
(Invitrogen, Carlsbad, CA, USA). 5’ cDNA ends were amplified by nested PCR 
with forward primers complimentary to the ligated RNA Oligo (5’ RACE-F and 
5’RACE-F Nested) and Kcnv2-specific reverse primers (5’ RACE-R and 5’ 
RACE-R Nested) (Table 3.1; Figure 3.1). The PCR product was gel-purified and 
cloned into the pCR4-TOPO sequencing vector (Invitrogen, Carlsbad, CA, USA) 
and transformed into One Shot TOP10 Competent Cells (Invitrogen, Carlsbad, 
CA, USA). Plasmid DNA was isolated with the QIAprep Spin Miniprep Kit 
(Qiagen, Germantown, MD, USA) and Sanger sequenced with the M13R primer 
(Table 3.1). Insert sequences were aligned to the C57BL/6J Kcnv2 reference 
sequence and analyzed using Sequencher software (Gene Codes, Ann Arbor, 
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MI, USA) to determine the genomic location of the 5’ terminus of each RACE 
product.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 5’ RACE Strategy 
5’ RACE products were generated using the GeneRacer Kit (Invitrogen, 
Carlsbad, CA, USA). RACE products were cloned into the pCR4-TOPO 
sequencing vector (Invitrogen, Carlsbad, CA, USA) for sequencing, and the 
resulting sequences were aligned to the C57BL/6J Kcnv2 reference sequence 
and analyzed using Sequencher software (Gene Codes, Ann Arbor, MI, USA). 
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3’ Rapid Amplification of cDNA Ends 
Poly(A) RNA was isolated from B6 and SJL whole-brains as described 
above. The poly(A) RNA was used as a template to produce RACE-ready cDNA 
using the GeneRacer Kit (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s protocol. Briefly, cDNA was reverse transcribed from poly(A) RNA 
with SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) using 
the GeneRacer Oligo dT Primer (Table 3.1). 3’ cDNA ends were then amplified 
by nested PCR with Kcnv2-specific forward primers (3’ RACE-F; 3’ RACE-F 
Nested) and reverse primers complementary to the sequence of the Oligo dT 
Primer that was used for reverse transcription (3’ RACE-R and 3’ RACE-R 
Nested) (Table 3.1; Figure 3.2). Nested PCR products were gel-purified, cloned, 
and sequenced as described above to determine the genomic location of the 3’ 
termini of each RACE product.  
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Figure 3.2 3’ RACE Strategy  
3’ RACE products were generated with the GeneRacer Kit (Invitrogen, Carlsbad, 
CA, USA) and analyzed as described for 5’ RACE.  
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Ribonuclease Protection Assay 
Poly(A) RNA was isolated from B6 or SJL eyes as described above. An 
antisense RNA probe labeled with incorporated biotin-16-labeled-UTP (4:1 
labeled:unlabeled nucleotide) and directed against the mouse β-actin transcript 
was transcribed from the T3 promoter of linearized pTRIPLEscript plasmid 
containing 250 bp of mouse β-actin gene (Ambion, Austin, TX, USA) using the 
MAXIscript In Vitro Transcription Kit (Life Technologies, Grand Island, NY, USA). 
For generation of an antisense RNA probe directed to overlap the predicted 5’ 
terminus of the Kcnv2 transcript (258 bp to 16 bp upstream of the Kcnv2 start 
codon), a DNA template was PCR amplified from the B6 BAC clone RP24-
537C5, containing the Kcnv2 genomic region 63.6 kb upstream of the start codon 
and 37.3 kb downstream of the stop codon, with RPA-F and RPA-R primers 
(Table 3.1). The resulting product was cloned into the pCR4-TOPO plasmid 
(Invitrogen, Carlsbad, CA, USA), and the sequence was verified by Sanger 
sequencing. The resulting plasmid DNA was linearized by restriction enzyme 
digest (NotI) and used as template to transcribe the antisense RNA probe with 
incorporated biotin-16-labeled-UTP (4:1 labeled:unlabeled nucleotide) using the 
MAXIscript In Vitro Transcription Kit (Life Technologies, Grand Island, NY, USA). 
The full-length β-actin and Kcnv2 probes were gel purified following 
electrophoresis on an 8 M urea 5% acrylamide gel, by overnight recovery in 
elution buffer (0.5M ammonium acetate, 1 mM EDTA , and 0.2% SDS), ethanol 
precipitation, and resuspension in nuclease-free water. RNA samples (0.36 µg 
mouse eye-derived poly(A) RNA, 10 µg torulla yeast RNA, or 1 µg mouse liver-
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derived RNA) were co-precipitated with the appropriate probe (300 pg α-Kcnv2 
or 300 pg α-β-actin), resuspended in 10 µL of Hybridization Buffer III, denatured 
for 4 minutes (95° C), and hybridized overnight at 42° C. 150 µL of RNase 
Digestion III Buffer with or without RNaseA/RNase T1 Mix (1:100 dilution) was 
added to the hybridization reactions and the mixtures were incubated for 30 
minutes at 37° C. Digestion reactions were inactivated by addition of 225 uL 
RNase Inactivation Solution III and ethanol precipitated. Protected probe 
fragments were resuspended in 10 uL of Gel Loading Buffer II and separated by 
electrophoresis through a denaturing polyacrylamide gel (5% acrylamide, 8M 
urea). Separated fragments were then electrolytically transferred to a positively-
charged nylon membrane and visualized by chemiluminescent detection using 
the BrightStar BioDetect system (Ambion, Austin, TX, USA) according to the 
manufacturer’s protocol.  
Generation of Luciferase Reporter Constructs 
A 7.3 kb fragment spanning -5.9 kb to +1.4 kb from the Kcnv2 start codon 
was digested from RP24-537C5 B6 BAC DNA with SnaBI and SacII, gel purified, 
and cloned into the multiple cloning site of the pGEM-T Easy Vector (Promega, 
Madison, WI, USA) between the EcoRI and SacII sites. From this construct a 5.8 
kb fragment corresponding to the region -5925 bp to -102 bp from the Kcnv2 start 
codon was digested with ApaI and MluI, gel purified, and cloned into the multiple 
cloning site of the promoterless pGL3-Basic luciferase reporter vector (Promega, 
Madison, WI, USA) between the SmaI and MluI sites (upstream of the firefly 
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luciferase gene) to generate pGL3-Basic-5925. From this construct we generated 
a 5’ deletion series of reporter constructs by excising fragments from the 5’ end 
of the Kcnv2 insert with restriction enzymes, gel purifying the remaining 
construct, and re-ligation (Figure 3.3). pGL3-Basic-2818, containing a fragment 
corresponding to the region -2818 bp to -102 bp from the Kcnv2 start codon, was 
generated by excising the region between the MluI and SmaI sites; pGL3-Basic-
1924, containing a fragment corresponding to the region -1924 bp to -102 bp 
from the Kcnv2 start codon, was generated by excising the region between the 
two KpnI sites; and pGL3-Basic-373, containing a fragment corresponding to the 
region -373 bp to -102 bp from the Kcnv2 start codon, was generated by excising 
the region between the PasI and MluI sites. We positioned the 3’ end of all of the 
constructs downstream of the predicted transcription start site to account for 
potential downstream promoter elements (Fig. 3.3). The direction of the insert 
corresponding to the region -373 bp to -102 bp from the Kcnv2 start codon was 
reversed by excision with KpnI and XhoI followed by a blunt-ended re-ligation of 
the excised fragment and insert. All of the constructs were prepped using the 
QIAfilter Plasmid Maxi Kit (Qiagen, Germantown, MD, USA), ammonium acetate 
precipitated, and verified by Sanger sequencing. 
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Figure 3.3 Luciferase Promoter Assay Constructs 
The genomic location of each of the 5’ KCNV2 genomic fragments used in the 5’ 
deletion series of luciferase reporter constructs are depicted in blue. The 
numbers represent the postion of the ends of the fragments relative to the 
KCNV2 start codon (bp).  
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Mammalian Cell Culture 
tSA201 cells were grown in 35x10 mm cell culture dishes in Dulbecco's 
modified Eagle's medium (DMEM, Life Technologies, Grand Island, NY, USA) 
supplemented with 10 % fetal bovine serum (FBS, Atlanta Biologicals, Norcross, 
GA, USA), 2 mm l-glutamine (Life Technologies, Grand Island, NY, USA) and 
penicillin (50 units ml−1)-streptomycin (50 µg ml−1) (PenStrep) (Life 
Technologies, Grand Island, NY, USA). Cells were maintained at 37° C and 5% 
CO2.  
Neuro-2a cells were grown as described above in Minimum Essential 
Medium (MEM, Life Technologies, Grand Island, NY, USA) supplemented with 
10% FBS (Atlanta Biologicals, Norcross, GA, USA) and Pen Strep (Life 
Technologies, Grand Island, NY, USA). 
Transfection 
Each pGL3 promoter-reporter vector was co-transfected with an internal 
control vector (phRL-TK, Promega, Madison, WI, USA) into tSA201 cells (grown 
to 70% confluency in 35x10mm dishes) with FuGene 6 transfection reagent (8.3 
µL) (Promega, Madison, WI, USA) (10:1 mass ratio promoter-reporter:control).  
Cells co-transfected with a positive control vector (pGL3-Control) and phRL-TK 
or empty pGL3-Basic and phRL-TK were included as positive and negative 
controls, respectively.  
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Promoter Assay 
One day post-transfection, each co-transfected plate of cells was spun 
down, resuspended in .5 mL Dulbecco's modified Eagle's medium without phenol 
red (Life Technologies, Grand Island, NY, USA), and used to seed quadruplicate 
wells of a 96-well plate (50,000 cells/well in 75 µL medium). Firefly and renilla 
luciferase luminescence values were assayed in the 96-well plate with the Dual-
Glo Luciferase Assay System (Promega, Madison, WI, USA) according to the 
manufacturer’s protocol on a SpectraMax M5 microplate reader (Molecular 
Devices, Sunnyvale, CA, USA) (integration time: 1000 ms). Background firefly 
and renilla luminescence values from untransfected cells (in relative 
luminescence units) were used for background subtraction, and the background 
subtracted firefly luciferase signal from each well was normalized to the 
background subtracted renilla signal. The normalized luminescence values were 
averaged for each co-transfection condition, and the averaged values were 
expressed as a percentage of the signal from the positive control condition (cells 
transfected with pGL3-Control and phRL-TK). Relative luminescence values from 
three independent experiments were compared by analysis of variance (ANOVA) 
with Fisher’s protected least significant difference (PLSD) post hoc tests. 
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Results 
Polymorphisms in the Kcnv2 Genomic Locus 
In order to determine the degree and location of sequence variation 
between the B6 and SJL strains in the genomic regions likely to contain cis-
regulatory elements, we sequenced the regions 3.3 kb upstream and 3.3 kb 
downstream of the Kcnv2 open reading frame. We observed 11 SNPs and 4 
insertions/deletions in the 3.3 kb region upstream of the start codon and 10 SNPs 
and 3 insertions/deletions in the predicted 3.3 kb 3’ UTR (Table 3.2). Any of 
these sequence variants could potentially occur in Kcnv2 cis-regulatory elements 
and contribute to phenotype variability by altering Kcnv2 steady-state expression 
levels.  
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Table 3.2 Sequence Variations Flanking the Kcnv2 Open Reading Frame 
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Table 3.2 Contd. Sequence Variations Flanking the Kcnv2 Open Reading 
Frame 
Determination of Kcnv2 Transcription Start Site Region 
To determine the location of the Kcnv2 TSS region we performed a 5’ 
RNA ligase-mediated rapid amplification of cDNA ends (RACE) analysis on CNS-
derived cDNA from B6 and SJL mice. The 5’ terminus of each RACE product 
represents the beginning of the Kcnv2 transcript from which it was made. Thus, 
we cloned and sequenced 142 Kcnv2 RACE products and aligned the 
sequences to the B6 reference sequence (GRCm38) to determine the genomic 
location of individual RACE products. The 5’ RACE product termini aligned to a 
region 230-130 bp upstream of the Kcnv2 start codon. This suggests that Kcnv2 
transcription occurs from any of several sites dispersed over a 100 bp TSS 
region at this location (Figure 3.4). This location is consistent with available RNA-
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seq data as well as TSS predictions from the Ensembl and UCSC genome 
databases (GRCm38) (Fig. 3.5) [188, 189].  
 
Figure 3.4 5’ RACE Summary 
Summary of 5’ RACE data. The RACE TSS Region (in red) represents the 
genomic location of the region in which the 5’ termini of RACE products aligned. 
The gray and orange bars represent the Kcnv2 5’ UTR and coding sequence, 
respectively, as predicted in Ensembl. (Modified from from www.ensembl.org 
(GRCm38 & h37)).  
 
Figure 3.5 Convergence of RACE, RPA, and RNA-seq Data 
Alignment of Kcnv2 TSS regions as predicted by RACE, RPA, and RNA-seq data 
from C57BL/6J and DBA/2J mouse strains (available in genenetwork.org). 
DBA/2J and SJL share a similar haplotype in this genomic region. Gray bar 
represents the TSS predicted in the UCSC Genome Browser (GRCm38). 
(Modified from UCSCbrowser.genenetwork.org.) 
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Next, to independently confirm the location of the Kcvn2 TSS, we 
performed a ribonuclease protection assay on eye-derived mRNA from B6 and 
SJL mice with an anti-sense RNA probe directed against the 5’ end of the 
predicted Kcnv2 transcript (-274 to -17 bp upstream of the start codon). Inferring 
from the genomic location of the full-length Kcnv2 probe and the size of the 
protected probe fragments, which ranged from ~215 bp to ~190 bp, the assay 
suggested that the Kcnv2 transcription start site region is located approximately 
230-205 bp upstream of the Kcnv2 start codon (Figure 3.6), which is consistent 
with both the 5’ RACE data and available RNA-seq data from genenetworks.org 
(Figure 3.5) [190].   
 
Figure 3.6 RNase Protection Assay 
Protected probe fragments were separated by electrophoresis and visualized by 
chemiluminescence. Lane M: RNA Century-Plus Marker. Lane 1: Kcnv2 probe 
hybridized with sample mRNA from mouse retina. Lane 2: Fully digested Kcnv2 
probe (no target control).  Lane 3: Full-length Kcnv2 probe w/ 105 bp of flanking 
vector  (no Rnase control). Lane 4: β-actin probe hybridized with RNA from 
mouse liver (positive control). 
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Identification of Kcnv2 Core Promoter Region 
To identify the Kcnv2 core promoter, we cloned genomic fragments 
upstream of the Kcnv2 TSS region into a promoterless luciferase reporter vector 
(pGL3Basic, Promega, Madison, WI, USA) to generate a 5’ deletion series of 
promoter-reporter constructs (Figure 3.3). We transiently transfected each 
construct into a human-derived cell line (tsA201) with a renilla luciferase-
expressing control vector (phRL-TK) and compared the resulting promoter 
activities using the Dual-Glo Luciferase Assay System (Promega, Madison, WI, 
USA). The reporter construct containing the Kcnv2 genomic fragment 
corresponding to the region 373-102 bp upstream of the Kcnv2 start codon 
exhibited significantly greater renilla-normalized firefly luciferase activity than the 
empty pGL3-Basic vector. This activity was abolished when the sequence was 
inverted in the reporter construct (Figure 3.7). These results suggest that the 
Kcnv2 core promoter, which we operationally defined as the minimal genomic 
sequence necessary to produce a basal level of promoter activity, is contained 
within the region 373-102 bp upstream of the Kcnv2 start codon. Additionally, we 
observed significant differences in the luciferase activities exhibited by the 
promoter-reporter constructs containing upstream Kcnv2 sequence, which 
suggests that the corresponding regions may contain additional cis-regulatory 
elements that influence Kcnv2 transcription. We also tested the constructs in a 
mouse neuroblastoma-derived cell line (Neuro-2a), but we did not observe 
luciferase signal from any of the Kcnv2-derived constructs (data not shown). This 
suggests that Kcnv2 may be actively repressed in this cell line.  
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Figure 3.7 Luciferase Promoter Assay 
Data are from three independent experiments, each with four technical replicates 
per condition. Firefly luciferase signals (relative luminescence units) from each 
well were background subtracted and normalized to renilla. The normalized 
values were averaged for each condition (four replicates / condition) and 
expressed as a percentage of the signal from the positive control vector (pGL3-
Control). 
Determination of 3’ Untranslated Region Organization 
To determine the organization of the Kcnv2 3’ UTR, we performed a 3’ 
RACE analysis on Kcnv2 RACE products generated from B6 and SJL-derived 
cDNA. The RACE products were cloned, sequenced, and analyzed as described 
for the 5’ RACE analysis to determine the genomic location of the 3’ termini of 
each RACE product, which represents the 3’ end of the Kcnv2 transcript from 
which it was derived. Consistent with the predicted transcript in the Ensembl and 
UCSC genome databases (GRCm38), the 3’ termini of the RACE products (n = 
15 alignments) aligned to a region located 3193-3284 bp downstream of the 
Kcnv2 stop codon (Figure 3.8) [188, 189].  
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Figure 3.8 5’ RACE Summary 
Summary of 5’ RACE data. The RACE TSS Region (in red) represents the 
genomic location of the region in which the 5’ termini of RACE products aligned. 
The gray and orange bars represent the Kcnv2 5’ UTR and coding sequence, 
respectively, as predicted in Ensembl. (Modified from www.ensembl.org 
(GRCm38 & h37)).  
Discussion 
Our previous studies suggested that Kcnv2 expression differences may 
underlie the strain differences in the epilepsy phenotype of Q54 mice. We 
hypothesized that regulatory sequence variation in the promoter and/or 3’ UTR of 
Kcnv2 influences seizure susceptibility by altering steady-state expression levels. 
Consistent with our hypothesis, regulatory variants with a relatively small effect 
on mRNA expression have been shown to modify complex clinical phenotypes in 
a number of diseases including cystic fibrosis, type 1 diabetes, female diarrhea 
predominant irritable bowel syndrome, and epilepsy [191-195].  
Kcnv2 is located on mouse chromosome 19 in a divergent haplotype block 
between B6 and SJL [149]. We observed a high degree of sequence variation 
between the B6 and SJL strains in the genomic regions flanking the Kcnv2 open 
reading frame, where cis-regulatory elements are likely to be located. Variation in 
cis-regulatory elements in the promoter region could affect the rate of Kcnv2 
transcription by altering transcription factor binding sites, and variation in the 3’ 
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UTR could disrupt binding sites for regulatory proteins and miRNAs that influence 
mRNA degradation.  
As an initial step towards identifying Kcnv2 cis-regulatory elements that 
influence strain differences in Kcnv2 expression, we sought to define the Kcnv2 
core promoter and 3’ UTR regions. Because the promoter region lies upstream of 
the TSS, we first identified the Kcnv2 TSS region by two independent methods, 
RACE analysis and RPA. Both the 5’ RACE and RNase protection assays 
suggested the Kcnv2 TSS region is located 230-130 bp upstream of the Kcnv2 
start codon. Thus, it appears that Kcnv2, which does not have a TATA box, is 
transcribed from multiple TSS dispersed over ~100 bp region. This observation is 
consistent with other TATA-less genes, which tend to be transcribed from a 
nondescript 50-100 bp region rather than from a single, defined nucleotide [196, 
197]. Neither assay indicated the presence of any 5’ non-coding exons, and the 
suggested TSS region location is consistent with RNA-seq data [190] and 
predicted transcripts in the Ensembl and UCSC genome databases (GRCm38) 
[188, 189]. The convergence of 5’ RACE and RNase protection assay data with 
available bioinformatic data suggests that we correctly defined the location of the 
Kcnv2 TSS region.  
We used this information to generate a 5’ deletion series of luciferase 
reporter constructs to identify the Kcnv2 core promoter. The reporter construct 
containing the insert corresponding to the region 373-102 bp upstream of the 
Kcnv2 start codon exhibited a basal level of luciferase activity, which suggests 
that the cis-factors necessary for the proper initiation of transcription are 
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contained within this region. Consistent with the directional activity of a promoter, 
reversing the orientation of the insert in the reporter vector abolished its activity. 
These observations suggest that the Kcnv2 core promoter lies within the region 
373-102 bp upstream of the Kcnv2 start codon. We also observed significant 
differences in the luciferase activities of the promoter-reporter constructs 
containing additional Kcnv2 upstream sequence. This suggests that the region 
upstream from the Kcnv2 core promoter may contain proximal promoter 
elements that influence Kcnv2 expression. In the future, these regulatory 
elements can be identified by comparing the luciferase activities of parallel B6 
and SJL-derived reporter constructs in cultured hippocampal neurons.  
To determine the organization of the Kcnv2 3’ UTR, we performed a 3’ 
RACE assay. The results of this assay suggest that the 3’ UTR extends between 
3193-3284 bp downstream of the Kcnv2 stop codon. This location is consistent 
with the predicted 3’ UTR in the Ensembl and UCSC genome databases 
(GRCm38). Additionally, there is a consensus polyadenylation sequence located 
3256 bp downstream from the Kcnv2 stop codon, which further supports the 
results of the RACE assay. Thus, it is likely that we correctly defined the 3’ 
terminal region of the Kcnv2 transcript. However, it should be noted that 
interpretation of the 3’ RACE results is complicated by the presence of a genomic 
21 bp poly-A tract immediately downstream from the predicted 3’ UTR. It is 
possible that this poly-A tract acts as an erroneous binding site for the 
GeneRacer Oligo dT primer used to reverse transcribe the cDNA from which the 
RACE products were amplified. This would result in truncated RACE products. 
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An RNase protection assay with an antisense RNA probe directed against the 3’ 
end of the Kcnv2 transcript would further validate the results of the RACE assay.  
In the future, the effect of 3’ UTR sequence variation between strains on 
the rate of mRNA degradation could be determined by treating cultured 
hippocampal neurons from B6xSJL.F1 mice with Actinomycin-D to inhibit 
transcription.  An allele specific qRT-PCR could then be performed on samples 
taken at various timepoints after treatment to compare the relative amounts of 
remaining B6 or SJL-derived Kcnv2 transcript. If it is determined that there are 
allelic differences in mRNA degradation, replacing specific regions of the B6-
derived 3’ UTR with SJL-derived sequence in reporter constructs could help to 
identify the regulatory elements responsible.  
 The aforementioned studies are focused on the Kcnv2 promoter and 3’ 
UTR regions. While these regions are likely to contain cis-regulatory elements 
that influence Kcnv2 expression, it is possible that distal enhancers or silencers 
also act to influence Kcnv2 expression. If sequence variation in cis-regulatory 
elements within the promoter and/or 3’ UTR regions fails to account for the strain 
differences in Kcnv2 expression, it may be necessary to investigate more distal 
regions for potential Kcnv2 regulatory elements.  
In the present studies we defined the regions where Kcnv2 cis-regulatory 
elements are likely to be located. These studies will provide the foundation for 
future studies to determine the effect of sequence variation in these regions on 
Kcnv2 expression. Together, these studies will help determine the molecular 
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basis of the Kcnv2 modifier effect and advance our knowledge of the 
mechanisms by which genetic modifiers influence epilepsy.  
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CHAPTER IV  
DE NOVO KCNB1 MUTATIONS IN EPILEPTIC ENCEPHALOPATHY∗ 
Introduction 
Epileptic encephalopathies are a heterogeneous group of severe 
childhood-onset epilepsies characterized by refractory seizures, 
neurodevelopmental impairment, and poor prognosis [26]. The developmental 
trajectory is normal prior to seizure onset, after which cognitive and motor delays 
become apparent. Ongoing epileptiform activity adversely affects development 
and contributes to functional decline. Therefore, early diagnosis and intervention 
may improve long-term outcomes [198-200]. 
Recently, there has been significant progress in identifying genes 
responsible for epileptic encephalopathies, and de novo mutations have been 
reported in approximately a dozen genes, including SCN1A, SCN2A, SCN8A, 
KCNQ2, HCN1, GABRA1, GABRB3, STXBP1, CDKL5, CHD2, SYNGAP1, and 
ALG13 [60, 201-204]. The majority of mutations reported are in genes encoding 
voltage-gated ion channels, neurotransmitter receptors and synaptic proteins. 
There is considerable phenotype heterogeneity, with mutations in the same gene 
resulting in different clinical presentations, as well as locus heterogeneity, with 
mutations in different genes resulting in the same syndrome. Further, epileptic 
                                            
∗ Modified from: Torkamani, A., et al., De Novo KCNB1 Mutations in Epileptic 
Encephalopathy. Ann Neurol, 2014. 
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encephalopathy genes have substantial overlap with genes responsible for other 
neurodevelopmental disorders, including autism and intellectual disability [205-
207]. 
Due to the considerable phenotype and locus heterogeneity, it is difficult to 
predict appropriate candidate genes for testing in a particular patient. Therefore 
hypothesis-free approaches such as whole exome sequencing (WES) or whole 
genome sequencing (WGS) may be useful for uncovering causative variations in 
epileptic encephalopathies of unknown etiology. We aimed to identify the 
underlying genetic cause of epileptic encephalopathy in the proband by WES and 
WGS of a family quartet. 
Materials and Methods 
Study Subjects 
Study participants included ID9, parents ID9F and ID9M, and an 
unaffected sister ID9S. Adults provided written informed consent, with additional 
assent by ID9 and ID9S, under a protocol approved by the Scripps institutional 
review board. Consent for release of medical information for individual 2 was 
obtained from the parents. Clinical details are below and summarized in Table 
4.1. 
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Table 4.1 Clinical Features in Three Individuals with Epileptic 
Encephalopathy and KCNB1 Missense Mutations 
Individual Current Age 
(sex) 
Age 
of 
onset 
Seizure types Seizure control 
with anti-epileptic 
therapies? 
(treatments) 
Developmental 
Delay 
Brain MRI 
ID9 9 yo (female) 4 yrs Tonic-clonic; 
Tonic; Atonic;  
Focal;  
Focal with 
secondary 
generalization 
No 
(Topiramate, 
clobazam, 
levitiracetam, 
Depakote, 
carbamazepine, 
trileptal, 
lacosamide, 
clonazepam, 
oxcarbazepine) 
Yes (motor and 
language) 
Subtle volume 
loss in left 
hippocampus 
2 7 yo (male) 8 mos 
 
Tonic-clonic; 
Atonic; Focal; 
Infantile spasms 
No 
(ACTH, 
Topiramate, 
Depakote, 
pyridoxine; 
ketogenic diet) 
Yes (motor and 
language) 
normal 
3 
(Coriell 
ND27062) 
5 yo (female) 0 yrs Tonic-clonic; 
Atonic;  
Focal 
dyscognitive 
Atypical 
absence; 
Infantile spasms;  
unknown Yes (unspecified) normal 
 
 
Table 4.1 Contd. 
Individual EEG Other Family 
history 
of 
epilepsy 
Presumed 
causal 
variant 
Amino 
Acid 
Change 
Predicted Consequence 
Provean (score)  
SIFT (score) 
Polyphen2 (score) 
ID9 Mild diffuse 
slowing and 
abundant bi-
hemispheric 
multifocal 
epileptiform 
discharges 
Hypotonia;  
Strabismus; 
Migraine;  
 
No Chr20: 
47991056 
G/T 
S347R Deleterious (-4.996) 
Damaging (0.003) 
Probably Damaging 
(0.995) 
 
2 Hypsarrhythmia; 
diffuse 
polyspikes, 
diffuse 
polyspike-wave, 
right temporal 
spike and wave, 
left occipital 
spikes and 
series of bursts 
of diffuse 
polyspikes 
Hypotonia 
Strabismus; 
Tremulousness; 
Non-verbal; 
Stereotyped 
handwringing 
movements; 
In-turning of 
feet 
 
No Chr20: 
47990962  
C/T 
 
G379R Deleterious (-7.926) 
Damaging (0.000) 
Probably Damaging 
(1.000) 
 
3 
(Coriell 
ND27062) 
unspecified Cerebral palsy Yes 
(Absence 
epilepsy 
in great 
uncle) 
Chr20: 
47990976 
G/A 
T374I Deleterious (-5.945) 
Damaging (0.000) 
Probably Damaging 
(0.999) 
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Individual ID9 is a 9-year-old female with epileptic encephalopathy, 
hypotonia, developmental delays, cognitive impairment, and intermittent 
agitation. Pre- and perinatal histories were unremarkable, although hypotonia 
and excessive somnolence were noted early. Motor milestones were delayed, 
with sitting at 9 months, walking at 20 months, and persistent clumsiness. 
Language acquisition was delayed with regression at age 18 months. Motor, 
language and behavior have fluctuated but overall there has been forward 
developmental progress. Onset of generalized tonic-clonic seizures (GTCS) was 
at 4.75 years of age, although behavioral manifestations likely representing other 
seizure types were present earlier. Multiple seizure seimiologies were reported 
including rare GTCS, head drops, and more common facial twitching with 
drooling, eye fluttering, gagging, vomiting and stiffening. Rare GTCS are 
controlled with levetiracetam and clonazepam, but other seizure types have been 
poorly controlled with multiple therapies that were ineffective or limited by side 
effects (Table 4.1). In addition, the patient experiences sumatriptan-responsive 
migrainous episodes consisting of headache, abdominal discomfort, photophobia 
and lethargy. 
Brain MRI showed subtle asymmetric volume loss in left hippocampus. 
Recent seven day video-EEG monitoring revealed mild diffuse slowing and 
abundant bi-hemispheric multifocal epileptiform discharges more prominent in 
right temporal and midparietal regions. Electroclinical seizures began in the left 
hemisphere, with two in centro-parietal areas and one without clear localization. 
Magnetoencephalography showed frequent epileptiform spikes during sleep (648 
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spikes observed over 50 minutes), with frequent trains of spikes. Source 
modeling showed epileptiform spike activity arising from bilateral posterior 
perisylvian regions. The first cluster of spikes (~55%) originated from the 
anterior-inferior aspect of the left parietal lobe, extending to the left superior 
temporal gyrus. The second cluster of spikes (~45%) originated from the right 
temporal-parietal junction. No propagations were observed.  
Muscle biopsy showed type 1 fiber predominance with mild generalized 
hypertrophy. There was slight elevation of plasma guanidinoacetate 2.5 (0.3-2.1 
µM) but not in the range typically associated with disease. There was mild 
elevation of cerebrospinal fluid (CSF) pyruvate with normal lactate [2.06 (0.5-2.2 
mM)/147 (0-75 µM)]. CSF 5-methyltetrahydrofolate was mildly reduced 36 (40-
128 nM). Folinic acid therapy has had unclear impact. Extensive additional work-
up was normal and included: karyotype, fragile X and Angelman syndrome 
testing, comparative genomic hybridization (CGH) Oligo-SNP Array, 
mitochondrial DNA Southern blot and mitochondrial DNA sequencing, plasma 
acylcarnitine, creatine phosphokinase (CPK), uric acid, biotinidase, ammonia, 
Vitamin B12, folate, homocysteine, folate receptor antibodies, lymphocyte 
pyruvate dehydrogenase activity, urine organic acids, urine creatine and 
guanidinoacetate, CSF glucose, protein, amino acids, neurotransmitter 
metabolite levels and pterins, muscle carnitine, CoQ10, and electron transport 
chain complex analysis. 
Individual 2 presented as a 2-yr-10-month male with poor seizure control, 
developmental delay, absent speech, stereotyped handwringing movements, and 
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progressive in-turning of feet requiring orthotic support. Prenatal and perinatal 
histories were normal. Development plateaued at 6 months and seizures began 
at 8 months of age, with hypsarrythmic EEG for which he was treated with ACTH. 
Although seizures were resistant to conventional treatment (Table 4.1), a 
gluten/casein/sugar/starch-free diet begun at 2.5 years of age resulted in seizure 
reduction to 3/day despite marked spike activity demonstrable on EEG. At 4 
years of age, seizures worsened and L-carnitine was added with subsequent 
amelioration. At 5 years of age, EEG was persistently abnormal with epileptiform 
discharges of multifocal origin including bursts of diffuse polyspikes, diffuse 
polyspike-wave, right temporal spike and wave, left occipital spikes and diffuse 
polyspike bursts lasting up to 4 minutes. Brain MRI studies at 9 months did not 
show structural, neuronal migration, or white matter abnormalities. He began 
walking at 2.5 years, and is presently interactive socially, though nonverbal. 
Extensive additional work-up was normal (Table 4.1). Genetic testing for 
mutations associated with SCN1A, MECP2, CDKL5, FOXG1, ARX, Fragile X, 
Pitt-Hopkins and Angelman syndromes were negative. Tests for plasma and 
cerebrospinal fluid (CSF) amino acid concentrations, urine organic acid levels, 
CSF neurotransmitter levels, lysosomal enzymes, very long chain fatty acids 
(VLCFA), neuronal ceroid lipfuscinosis (NCL) 1 & 2, urine sulfocysteine, 
congenital disorders of glycosylation (CDG), and oligo array were all normal. 
Clinical WES was performed by GeneDx and reported variants were confirmed 
by Sanger sequencing. 
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Individual 3 (Coriell ND27062) was ascertained by the Epilepsy 
Phenome/Genome Project [208] as part of a patient cohort with infantile spasms 
and/or Lennox-Gastaut syndrome [60]. Seizure onset occurred during the first 
year of life and seizure types include tonic-clonic, atypical absence, atonic, 
infantile spasms and focal dyscognitive (Table 4.1). EEG findings were 
unspecified, while imaging studies were reported as normal. 
Whole Exome, Whole Genome Sequencing, Variant Calling, and Filtration 
Genomic DNA was extracted from blood using the QiaAmp system 
(Qiagen, Valencia, CA). Enriched exome libraries were prepared using the 
SureSelect XT enrichment system (Agilent, Santa Clara, CA). WES was 
performed on an Illumina HiSeq2500 instrument with indexed, 100-bp, paired-
end sequencing. Reads were mapped to the hg19 reference genome using BWA 
[209], variant calling and quality filtration was performed using GATK best 
practices variant quality score recalibration [210-212]. Mean coverage of 97 to 
124-fold was achieved for each subject with 94-95% of the target exome covered 
by >10 reads (Table 4.2). Libraries for low-pass WGS were prepared using the 
NEBNext DNA Library Prep System (New England Biolabs, Ipswich, MA). WGS 
was performed on an Illumina HiSeq2500 with 100-bp indexed, paired-end 
sequencing. Mean coverage of 4 to 7-fold was achieved for each subject with 
~64.3% of the genome covered by >5 reads (Table 4.2). Copy number variants 
(CNVs) were identified by CNVNator [213]. 
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Table 4.2 Whole Exome and Whole Genome Sequencing Coverage 
  Whole Exome Sequencing Whole Genome Sequencing 
Sample Coverage (Mean) 
% Target 
Exome with at 
least 10 Reads 
Coverage 
(Mean) 
% Genome 
Redundancy 
of 5 Reads 
ID9 – Proband 109 94.5% 4.1 37.9% 
ID9F – Father 109 94.6% 6.0 66.7% 
ID9M – Mother 124 94.9% 6.9 75.2% 
ID9M – Sister 97 94.2% 7.2 77.4% 
 
Variant annotation was performed using the Scripps Genome Annotation 
and Distributed Variant Interpretation Server (SG-ADVISER) 
(http://genomics.scripps.edu/ADVISER/) as previously described [214]. A series of 
filters were applied to derive a set of candidate disease-causing variants (Table 
4.3): (1) population-based filtration removed variants present at >1% allele 
frequency in the HapMap [215] or 1,000 Genomes [216], NHLBI Exome 
Sequencing Project (http://evs.gs.washington.edu/EVS/), or Scripps Wellderly 
populations (individuals over the age of 80 with no common chronic conditions 
sequenced on the Complete Genomics platform); (2) annotation-based filtration 
removed variants in segmental duplication regions that are prone to produce 
false positive variant calls due to mapping errors [217]; (3) functional impact-
based filtration retained only variants that are non-synonymous, frameshift, 
nonsense, or affect canonical splice-site donor/acceptor sites, and (4) 
inheritance-based filters removed variants not present in the trio in a manner 
consistent with affectation status. Following filtering, retained variants were 
confirmed by Sanger sequencing. 
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Table 4.3 WES Variant Filtration for Individual ID9 
Variant Type #  in Family 
Total Variants 101,797 
  Rare Variants (<1% allele frequency) 18,475 
    Not in Segmental Duplication 13,463 
      Nonsynonymous, Truncating, or Splice Site 1,053 
        De Novo Inheritance 2 
        Homozygous or Compound Heterozygous Inheritance 3 
 
Locus Specific Mutation Rate Estimate 
The KCNB1 locus specific mutation rate was determined as described 
[218]. Human and chimpanzee alignments of the protein coding portion of exons 
and intronic essential splice sites were considered. The KCNB1 mutation rate per 
site is 2.71x10-3 differences per bp of aligned sequence. Assuming a divergence 
time of 12 million years between chimpanzee and human and a 25 year average 
generation time, the KCNB1 locus specific mutation rate per site per generation 
is 5.65x10-9. The probability of observing de novo mutation events was estimated 
using the Poisson distribution: 
𝑃𝑋;	  𝜇=	  [(𝑒−𝜇)(𝜇𝑋)]/𝑋! 
where X is the number of de novo events observed and µ is the average number 
of de novo events based on the locus specific mutation rate. 
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Plasmids and Cell Transfection 
Mutations were introduced into full-length human KV2.1 cDNA engineered 
in plasmid pIRES2-Ds-Red-MST [117] by QuikChange mutagenesis (Agilent). 
Wildtype human KV2.1 cDNA was subcloned into the pIRES2-smGFP expression 
vector. Expression of wildtype and mutant KV2.1 in CHO-K1 cells was achieved 
by transient transfection using FUGENE-6 (Roche) and 0.5 µg of total cDNA (1:1 
mass ratio). Expression of wildtype alone was achieved by transfection with 
pIRES2-smGFP-WT-KV2.1 plus empty pIRES2-DsRed-MST, while expression of 
mutant alone was performed with pIRES2-DsRed-MST-mutant-KV2.1 and empty 
pIRES2-smGFP. Co-expression of mutant and wildtype was achieved by co-
transfection with pIRES2-smGFP-WT-KV2.1 and pIRES2-DsRed-MST-mutant-
KV2.1 or pIRES2-dsRed-MST-WT-KV2.1. Following transfection cells were 
incubated for 48 hours before use in experiments. 
Cell Surface Biotinylation 
Proteins on the surface of CHO-K1 cells transfected with wildtype and/or 
mutant KV2.1 were labeled with cell membrane-impermeable Sulfo-NHS-Biotin 
(Thermo Scientific). Following quenching with 100 mM glycine, cells were lysed 
and centrifuged. Supernatant was collected and an aliquot was retained as the 
total protein fraction. Biotinylated surface proteins (100 µg per sample) were 
recovered from the remaining supernatant by incubation with strepavidin-agarose 
beads (Thermo Scientific) and eluted in Laemmli sample buffer. Total (1 µg per 
lane) and surface fractions were analyzed by Western blotting using mouse anti-
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KV2.1 (1:500; NeuroMab, clone K89/34), mouse anti-transferrin receptor (1:500; 
Invitrogen, #13-6800), rabbit anti-calnexin (H70)(1:250; Santa Cruz, sc-11397) 
primary antibodies, and peroxidase-conjugated mouse anti-rabbit IgG (1:100,000 
Jackson ImmunoResearch) and goat anti-mouse IgG (1:50,000, Jackson 
ImmunoResearch) secondary antibodies. Blots were probed for each protein in 
succession, stripping in between with Restore Western Blot Stripping Buffer 
(Pierce). Western blot analysis was performed in triplicate on samples from three 
independent transfections. The order of anti-KV2.1and anti-transferrin receptor 
antibodies was alternated, with transferrin receptor probed first in two of three 
experiments. Selectivity of biotin labeling for cell surface was confirmed by 
probing with calnexin following detection of KV2.1 and transferrin receptor. 
Calnexin signal was consistently present in total protein lanes and absent in 
surface fraction lanes. Densitometry was performed using NIH ImageJ software. 
To control for protein loading, KV2.1 bands were normalized to the corresponding 
transferrin receptor band. For each genotype, the normalized values were then 
expressed as a ratio of surface:total expression. Normalized total, surface and 
surface:total ratios were compared between genotypes using one-way ANOVA.  
Electrophysiology 
Whole cell patch-clamp recordings were performed as described [117], 
except recording solutions were altered to achieve appropriate voltage-control. 
The external solution contained (in mM): 132 XCl [where X is Na+ except when 
molar substitution for K+, Rb+ or N-methyl-D-glucamine (NMDG+) is indicated in 
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the figure], 4.8 KCl, 1.2 MgCl2, 2 CaCl2, 10 glucose, and 10 HEPES, pH 7.4. The 
internal solution contained (in mM): 20 K-aspartate, 90 NMDG-Cl, 1 MgCl2, 1 
CaCl2, 11 EGTA, 10 HEPES, and 5 K2ATP, pH 7.3. When cells expressing 
mutant channels alone or co-expressed with wildtype KV2.1 (KV2.1-WT) were 
held at -80 mV, they exhibited large currents that prevented adequate voltage 
control. Therefore, a holding potential of -30 mV was used for experiments. 
Whole cell currents were measured from -80 to +60 mV (in 10 mV, 500 msec 
long steps) from a holding potential of -30 mV followed by a 500 msec step to 0 
mV (tail currents). Voltage-dependence of activation was evaluated from tail 
currents measured 10 msec after stepping to 0 mV from -40mV to +30mV and fit 
to the Boltzmann equation. Kinetic analysis of activation rate was performed by 
exponential fit of the first 50 msec of current induced after a voltage step from the 
holding potential.  
For cation selectivity experiments, recording solutions were altered as 
follows: sucrose dilution was performed by adding 300 mM sucrose solution 10:1 
(v/v) to the external solution described above. For determining permeability 
ratios, the internal solution was modified to contain (in mM): 110 K-aspartate, 1 
MgCl2, 1 CaCl2, 11 EGTA, 10 HEPES, and 5 K2ATP, pH 7.3 and equimolar 
replacement of extracellular sodium with the monovalent cations K+, Rb+ and 
NMDG+. The permeability ratio (PX/PNa) was calculated from measured reversal 
potentials (Erev) according to the following equation [73]: 
Erev = (RT/F) ln(Px[X+]o / PK+[Na+]i 
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where R is the gas constant, T is absolute temperature, F is Faraday’s constant, 
X+ is the monovalent cation in the extracellular solution, and PX is permeability of 
the X+ cation.  
Data for each experimental condition were collected from ≥3 transient 
transfections, and analyzed and plotted using Clampfit (Molecular Devices) and 
Graphpad Prism5 (Graphpad Software). Currents were normalized for membrane 
capacitance and shown as mean ± SEM, and number of cells used for each 
experimental condition is listed in Table 4.5. Statistical significance was 
determined using unpaired Student’s t test (Graphpad). P values are provided in 
the figures or figure legends. 
Results 
We employed WES (~100X coverage) and WGS (~5X coverage) of the 
proband (ID9), unaffected father (ID9F), unaffected mother (ID9M), and 
unaffected sister (ID9S) to identify the molecular cause of an epileptic 
encephalopathy. Filtering of WES variants was done under the assumption that 
disease in ID9 was the result of a heterozygous de novo mutation, but we also 
considered simple and compound recessive models. Variants discovered by 
WES were processed through a series of population-, variant annotation-, 
functional-impact-, and inheritance-based filters, to identify a set of candidate 
disease-causing variants (Table 4.3).  
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Table 4.4 Inheritance of Validated Candidate Variants in Individual ID9 
WES Genotype Predicted Consequence 
Gene ID1 Status Amino Acid Change ID9 ID9F ID9M ID9S Provean SIFT Polyphen 2 
KCNB1 de-novo S347R 01 00 00 00 deleterious (-4.996) 
damaging 
(0.003) 
probably 
damaging 
(0.995) 
MLST8 de-novo Q302R 01 00 00 00 neutral (-2.12) 
tolerated 
(0.203) 
benign 
(0.114) 
HRNBP3 homozygous Y5H 11 01 01 00 deleterious (-3.54) 
damaging 
(0.000) 
benign 
(0.446) 
V939M 01 00 01 01 neutral (-2.08) 
damaging 
(0.006) 
probably 
damaging 
(0.982) NLRP1 
compound 
heterozygou
s R834C 10 01 00 00 neutral (-0.46) 
tolerated 
(0.216) 
benign 
(0.000) 
A941T 01 00 01 01 neutral (-1.38) 
tolerated 
(0.215) 
benign 
(0.009) 
BAHCC1 
compound 
heterozygou
s E1990K 10 01 00 00 neutral (-0.91) 
tolerated 
(0.168) 
possibly 
damaging 
(0.900) 
Genotypes: 0 – reference allele, 1 – alternate allele 
 
Sequence coverage and detailed variant data are presented in Table 4.2. 
CNVs were also interrogated by WGS, however, no CNVs consistent with 
disease segregation were identified. This process identified de novo missense 
variants in 2 candidate genes, KCNB1 and MLST8 (Table 4.4). Under other 
genetic models, we identified a homozygous missense variant in HRNBP3 and 
compound heterozygous variants in NLRP1 and BAHCC1 (Table 4.4). Of all the 
identified variants, the KCNB1 variant was deemed the most likely candidate 
based on the de novo inheritance pattern, the function of KCNB1 and its 
relationship to other epilepsy genes, and the predicted deleterious consequence 
on protein function by multiple algorithms (Table 4.4). KCNB1 encodes the alpha 
subunit of the KV2.1 voltage-gated potassium channel, a delayed rectifier 
potassium channel that is an important regulator of neuronal excitability. The 
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S347R variant is located in the pore domain that is necessary for ion selectivity 
and gating (Figs. 4.1 & 4.2). 
 
 
Figure 4.1 Location of KV2.1 Mutations Mapped onto the Crystal Structure 
of a KV2.1/Kv1.2 Chimera 
Extracellular side of channel tetramer. S347 (green) lies at the interface between 
the voltage sensor (blue) and pore (white) domains. T374 (teal) lies adjacent to 
the selectivity filter, while G379 (red) lies in the selectivity filter (PDB 29R9)[219] 
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We identified two additional unrelated patients with epileptic 
encephalopathy and de novo missense variants in KCNB1 discovered by WES. 
Individual 2 presented with a sporadic epileptic encephalopathy of unknown 
cause (Table 4.1). After a series of negative genetic and metabolic tests, he was 
referred for clinical WES. From that analysis it was determined that he had a 
single de novo missense variant in KCNB1. The variant G379R, located in the 
selectivity filter of KV2.1, was predicted to be deleterious by functional impact 
algorithms (Figs. 4.1 & 4.2; Table 4.1). Additional inherited variants included a 
heterozygous splice site mutation in the NPC2 gene (IVS4+1 G>A) inherited from 
his unaffected father and a variant of unknown significance in GRIN2A (A1276G) 
inherited from his unaffected mother. Neither of these transmitted variants was 
thought to be causative for principal phenotypes of individual 2, although they 
may contribute by modifying the overall expression of the clinical phenotype. 
Inheritance of NPC type 2 is generally recessive, and the clinical phenotype of 
individual 2 was not consistent with NPC type 2. The GRIN2A A1276G variant is 
a known SNV that was inherited from the unaffected mother and exists in the 
general population (0.1% MAF in European Americans). A1276G is a 
conservative substitution in an alternatively spliced portion of the GRIN2A gene 
at a position that does not show a high degree of evolutionary conservation and 
was predicted to be benign by multiple functional impact algorithms (Provean: 
neutral (-0.78); SIFT: tolerated (0.284; Polyphen2: benign (0.376)). 
Individual 3 was recently reported as part of an epileptic encephalopathy 
exome sequencing study by the Epi4K consortium [60]. She presented with 
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early-onset epileptic encephalopathy and cerebral palsy (Table 4.1). A de novo 
missense variant in KCNB1 was reported for individual 3, with no additional de 
novo variants reported [60]. The variant T374I is located in the pore domain of 
KV2.1 and was predicted to be deleterious by functional impact algorithms (Fig. 
4.1; Table 4.1). 
Given the locus-specific mutation rate of KCNB1 (5.65x10-9 mutation 
rate/base/generation), the probability of identifying three independent mutations 
is low (P<1.1x10-13), providing statistical evidence that these variants may be 
pathogenic. The altered residues show a very high degree of evolutionary 
conservation (Fig. 4.2), with T374 and G379 being invariant through the ancestral 
KcsA bacterial potassium channel. Further, all three KCNB1 variants are located 
in the functionally important pore domain of the KV2.1 channel protein. Serine 
347 is located in the pre-pore transmembrane segment and threonine 374 is 
located in the pore helix. Glycine 379 is part of the critical “GYG” motif that 
defines the potassium selectivity filter (Figs. 4.1 & 4.2).  
Figure 4.2 Evolutionary Conservation of KV2.1 
Multiple Alignment of KV2.1 Species Orthologs. Mutated amino acids are shaded 
and functional sub-domains of the pore region are indicated (Clustal Omega) 
[220]. 
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Effects of the KCNB1 variants on KV2.1 channel function were evaluated 
following transient expression in CHO-K1 cells. Expression of each mutant in 
CHO-K1 cells resulted in total and cell surface expression similar to the wildtype 
channel, with no significant genotype-dependent differences in total (F3,8=1.767, 
p=0.213), surface (F3,8=0.017, p=0.997) and surface:total (F3,8=0.266, p=0.848) 
expression of KV2.1. This indicates that the mutations do not interfere with 
protein expression or trafficking of channels to the cell surface (Fig. 4.3).  
 
Figure 4.3 KV2.1 Cell Surface Expression 
Mutant KV2.1 proteins are expressed and trafficked to the cell surface. Cell 
surface expression was measured using cell surface biotinylation of CHO-K1 
cells transfected with wildtype or mutant KV2.1. Total and surface fractions of 
KV2.1 were detected with anti-KV2.1 antibody. Endogenous transferrin receptor 
levels were measured as a loading control.  
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Figure 4.4 Functional Consequence of KV2.1 Mutations 
(a) CHO-K1 cells were held at -30mV and whole cell currents were recorded from 
-80 to +60 mV in 10 mV steps for 500 msec followed by a 500ms step to 0mV to 
record tail currents. (b) Average whole-cell current traces recorded from non-
transfected CHO-K1 cells and CHO-K1 cells transiently expressing wild-type or 
mutant (G379R, S347R, T374I) KV2.1 channels, or co-expressing wild-type plus 
mutant channels. (c) Current density–voltage relationships measured from CHO-
K1 cells expressing mutant, wild-type, or co-expressing wild-type and mutant 
KV2.1 channels. Currents were normalized to cell capacitance (pF). (d) Voltage 
dependence of steady-state activation. Tail currents were normalized to peak 
amplitude and fit with Boltzmann function. Biophysical parameters of voltage-
dependence are detailed in Table 3.5. (e) The time constant of activation was 
determined from exponential fit of individual current traces.  
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Expression of KV2.1-WT resulted in large voltage-dependent potassium 
currents with characteristic outward rectification and late inactivation (Fig. 4.4b-
c). In contrast, expression of each of the three mutants yielded small currents 
with linear current-voltage relationships (Fig. 4.4b-c). These aberrant currents 
were blocked by gadolinium (Gd3+), strongly suggesting that the currents are 
pore-mediated (Fig. 4.5).  
Figure 4.5 GdCl3 Block of Mutant KV2.1 Channels 
Representative traces of control and Gd+3 block at +60 mV of wild-type  
(86±2.1%, n=5) or mutant channels (S347R (94±3.7%, n=3), G379R (79±4.2%, 
n=4), T374I (94±2.5%, n=3)). 
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Based upon the external and internal K+ concentrations used in these 
experiments, the theoretical reversal potential (Erev) for K+-selective currents is    
-47 mV. Expression of the mutant channels produced currents with depolarized 
Erev (S347R: -23.2±4.8 mV; G379R -14.0±4.5 mV; T374I -16.5±5.5 mV) 
indicating that the mutations affect ion selectivity. To test ion selectivity, the 
external solution was diluted 1:10 with 300 mM sucrose. Under these conditions, 
a depolarizing shift in Erev would indicate anion selectivity, while a hyperpolarizing 
shift would indicate cation selectivity. Dilution of the extracellular solution 
produced a hyperpolarizing shift in Erev confirming the current conducted was 
cation-selective (Fig. 4.6). Changes in cation selectivity were determined by 
measuring changes in Erev following molar replacement of extracellular sodium 
with monovalent cations. All three mutants exhibited loss of K+ selectivity, with 
K+/Na+ permeability ratios of 0.9 (Fig. 4.6; Table 4.5) compared to the reported 
14:1 ratio for KV2.1-WT [221]. 
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Figure 4.6 Ion Selectivity of Mutant KV2.1 Channels 
(a) Reversal potentials were determined by linear fit to y=mx+b in control bath 
and after bath was diluted 10-fold in 300mM sucrose solution. (b) Change in 
reversal potential after equimolar substitution of extracellular monovalent Na+. 
Table 4.5 Biophysical Properties of Voltage-dependence of Activation for 
Wild-type and Mutant KV2.1 Channels 
 Mean V1/2 ± S.E.M. Slope factor ± S.E.M. n 
Kv2.1-WT -4.1 ± 1.5 4.4 ± 0.4 12 
Kv2.1-WT + G379R 1.3 ± 2.0 * 5.2 ± 0.6 8 
Kv2.1-WT + S347R 2.8 ± 1.6 * 5.9 ± 0.5 8 
Kv2.1-WT + T374I 1.9 ± 1.5 * 5.7 ± 0.2 7 
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To investigate the effects of the mutant channels in a heterozygous 
background, we co-expressed each mutant with KV2.1-WT channel and 
compared to the wildtype channel expressed alone. Co-expression of KV2.1-WT 
with T374I, S347R, or G379R resulted in reduced current measured at test 
potentials ranging from 0 to +60 mV (Fig. 4.4c), depolarizing shifts in the voltage-
dependence of steady-state activation (Fig. 4.4d; Table 4.5; Fig. 4.7), and greater 
time constants of activation (τ) measured from +30 to +60 mV test potentials (Fig. 
4.4e; Fig. 4.7). The observed changes in kinetic parameters suggest that the 
mutant and wild-type subunits can form heterotetrameric channels. 
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Figure 4.7 Expanded View of Whole-cell Current Traces for Evaluation of 
Activation Kinetics of Wild-type KV2.1 Channel Alone or Co-expressed with 
Mutant Channels 
Expanded view of the first 50 msec of whole-cell currents following voltage 
change from -80mV to +60mV and normalized to peak current recorded from 
CHO-K1 cells transiently expressing KV2.1-WT (a) or co-expressing wild-type 
and mutant Kv22.1 channels ((b) G379R, (c) S347R, (d) T374I). 
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Discussion 
Co-occurrence of de novo variants in KCNB1 in three independent 
patients with overlapping clinical phenotypes that include epileptic 
encephalopathy with associated cognitive and motor dysfunction provides strong 
genetic evidence that the KCNB1 variants are likely pathogenic. Further evidence 
for a pathogenic effect of the KCNB1 mutations comes from functional studies of 
mutant KV2.1 channels. All three mutations, located within the pore domain of 
KV2.1, resulted in channels with similar dysfunctional features. 
Previous studies demonstrated that mutations in the pore region can result 
in altered ion selectivity [79, 82-84]. Consistent with this, each KV2.1 mutant 
exhibited voltage-independent, non-selective cation currents. When co-
expressed with wildtype channels, all KV2.1 mutants induced depolarizing shifts 
in the voltage-dependence of activation and reduced current density at more 
depolarized voltages. Further, co-expression of the KV2.1 mutants with wildtype 
channels resulted in inward currents in the voltage range where KV2.1 channels 
are normally closed, as evidenced by large inward currents observed when using 
a holding potential of -80 mV. These gain-of-function and dominant-negative 
functional defects are predicted to result in depolarized resting membrane 
potential and impaired membrane repolarization, with increased cellular 
excitability as a net consequence. 
KV2.1 is the main contributor to delayed rectifier potassium current in 
pyramidal neurons of the hippocampus and cortex [151-155]. Delayed rectifier 
potassium current is critical for membrane repolarization under conditions of 
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repetitive stimulation and acts to dampen high frequency firing. Reduction of 
delayed rectifier potassium current by Kcnb1 deletion in mice results in reduced 
thresholds to induced seizures, but not spontaneous seizures [222]. This 
suggests that loss of KV2.1 function predisposes neuronal networks to 
hyperactivity, resulting in a modest increase in seizure risk. In contrast, our 
results demonstrate that gain-of-function and dominant-negative effects result in 
epileptic encephalopathy. A similar phenomenon is observed with KCNQ2 
wherein heterozygous loss-of-function mutations result in benign familial 
neonatal seizures, while mutations with dominant-negative effects result in 
epileptic encephalopathy [126]. This suggests that variable functional defects 
resulting from different mutations in the same gene contribute to the pleiotropic 
effects observed for genes associated with neurodevelopmental disorders. 
In summary, our genetic and functional evidence identify mutation of 
KCNB1 as a cause of epileptic encephalopathy. This expands the considerable 
locus heterogeneity associated with epileptic encephalopathies [60, 201], 
suggesting that clinical exome sequencing may be useful for molecular 
diagnosis. Rapid genetic diagnosis is beneficial for appropriate disease 
management and may improve long-term outcomes in epileptic 
encephalopathies [198-200]. 
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CHAPTER V  
 
DISCUSSION 
Summary 
Rationale 
Epilepsy is a common neurological disease that affects more than 50 
million people worldwide [4]. The U.S. spends more than 12.5 billion dollars 
annually on epilepsy associated medical expenditures [181]. However, more than 
one-third of epilepsy patients do not have effective treatments for their epilepsy 
[20]. Although many factors contribute to epilepsy, the majority of epilepsy cases 
have an underlying genetic cause [35, 36]. 
The vast majority of heritable epilepsies are thought to be due to complex 
interactions between multiple genes, with only 1-2% attributed to single genes 
[35]. Nevertheless, identifying the genes involved in monogenic epilepsies can 
help to elucidate the etiology of more complex epilepsies. Many genes 
responsible for monogenic epilepsies have been identified in recent years. Most 
of these genes encode components of neuronal signaling, including voltage-
gated ion channels [35, 44, 165].  
Mutations in voltage-gated sodium channels are the leading cause of 
monogenic epilepsies. Over 900 mutations have been identified in the voltage-
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gated sodium channels SCN1A and SCN2A [55]. These mutations are 
associated with a number of epilepsy syndromes including febrile seizures, 
BFNIS, GEFS+, Lennox-Gastaut, DS, and Ohtahara syndrome [35, 42-44, 55-60, 
64, 67-70]. Family members who inherit identical mutations in voltage-gated 
sodium channels often exhibit variable phenotypes, which suggests that genetic 
variation at modifier loci may contribute to epilepsy phenotypes [42, 136, 223].  
Identifying and characterizing genetic modifiers of epilepsy can lead to a better 
understanding of the pathogenic mechanisms underlying epilepsy, and genetic 
modifiers may represent novel therapeutic targets for the treatment of epilepsy. 
Our lab previously identified the voltage-gated potassium channel subunit, 
Kcnv2, as a candidate modifier of epilepsy in the Q54 transgenic mouse model of 
epilepsy by genetic mapping and candidate gene analysis [140, 149]. 
Validation of Kcnv2 as a Genetic Modifier of Epilepsy 
Chapter II detailed experiments to validate Kcnv2 as a genetic modifier of 
epilepsy. We initially hypothesized that amino acid differences in Kv2.1 between 
the B6 and SJL strains would result in functional changes in the protein that 
would account for the disparate phenotypes. However, when we co-expressed 
either the B6 or SJL-derived Kv8.2 with Kv2.1 in CHO cells and performed 
whole-cell patch clamp recordings, we did not observe any such functional 
differences.   
To determine whether differences in Kcnv2 expression might contribute to 
the divergent phenotypes, we measured Kcnv2 transcript levels in the 
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hippocampus, the origin of seizures in the Q54 mice, and observed a threefold 
increase in hippocampal Kcnv2 expression in the seizure susceptible SJL mouse 
strain relative to the resistant B6 strain. We then tested the Kcnv2 modifier effect 
in vivo using a transgenic transfer approach and observed a positive correlation 
between increased expression of the Kcnv2 transgene and phenotype severity in 
multiple lines of Kcnv2;Q54 double-transgenic mice. Consistent with the 
functional analysis in CHO cells, there was not a significant correlation between 
the amino acid sequence of the Kcnv2 transgene and the phenotype. These 
results indicate that increased Kcnv2 expression is sufficient to exacerbate the 
seizure phenotype of Q54 mice and implicate Kcnv2 as a modifier of the Q54 
phenotype. Additionally, they suggest that sequence variation in Kcnv2 cis-
regulatory regions may underlie the modifier effect. Furthermore, the validation of 
Kcnv2 as a quantitative modifier substantiates the utility of our approach for 
identifying genetic modifiers and emphasizes the potential impact of genetic 
variation in non-coding regions of the genome on disease susceptibility.  
 
Identification and Characterization Kcnv2 Variants in Pediatric Epilepsy 
Patients 
Also detailed in Chapter II is the identification of two unique KCNV2 
variants (R7K and M285R) in pediatric epilepsy patients, both of which occur in 
highly conserved residues and, when co-expressed with Kv2.1 in CHO cells, 
result in increased suppression of Kv2.1-mediated delayed-rectifier potassium 
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current. This effect would be predicted to result in a hyperexcitable phenotype 
and is consistent with the predicted consequence of Kcnv2 overexpression in 
mice. The M285R variant, which occurred in the more severely affected patient, 
exhibited additional kinetic defects that would be predicted to delay channel 
opening. These observations suggest that the variants might contribute to the 
epilepsy phenotype of the patients. Both variants were inherited from an 
unaffected parent, suggesting that KCNV2 may interact with other genetic loci to 
influence epilepsy susceptibility. Although neither patient carried any pathogenic 
variants in SCN1A or SCN2A, it is possible that inherited genetic variation at 
other loci contributes to the phenotype. Together, these findings suggest that 
genetic variation in KCNV2 may contribute to human epilepsy, further validating 
KCNV2 as an epilepsy gene. Additionally, they implicate suppression of delayed 
rectifier potassium current as a potential factor contributing to epilepsy 
susceptibility. The identification of KCNV2 variants in human patients supports 
the idea that modifier genes identified in mice can provide clues into the etiology 
of human disease and highlights the value of identifying genetic modifiers in 
mice.  
Identification of Kcnv2 Regulatory Regions in Mouse 
Based on the observation that Kcnv2 acts as a quantitative modifier of the 
Q54 phenotype we hypothesized that sequence variation between the resistant 
B6 strain and the susceptible SJL strain in Kcnv2 cis-regulatory regions may 
influence epilepsy susceptibility by affecting steady-state expression. As the 
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promoter and 3’ UTR are the regions most likely to contain cis-regulatory 
elements, we sought to define these regions as a first step towards addressing 
our hypothesis. Because promoter regions of genes lie immediately upstream of 
the transcription start site, we first identified the Kcnv2 promoter using two 
independent methods, RNA ligase mediated rapid amplification of cDNA ends 
(RACE) and RNase protection assay (RPA). The results of both methods were in 
agreement with each other and with bioinformatic data available from multiple 
databases, suggesting that the RACE and RPA-defined transcription start site 
region was accurate.  
We next used the information from the RACE and RPA assays to design a 
5’ deletion series of luciferase reporter vectors containing sequence 
corresponding to the genomic region upstream of the Kcnv2 transcription start 
site to define the core promoter region. Our luciferase based promoter assays 
suggested that the Kcnv2 core promoter is contained within the region 373-102 
bp upstream of the Kcnv2 start codon. Variation in luciferase expression between 
the constructs containing Kcnv2 genomic inserts extending in the 5’ direction 
suggested that the regions upstream of the core promoter contain additional 
proximal promoter elements that may contribute to variability in Kcnv2 
transcription levels. We proposed future studies to determine whether sequence 
variation in these elements contributes to Kcnv2 expression differences between 
the B6 and SJL strains.  
Additionally, we performed a 3’ RACE assay to determine the 3’ UTR 
organization of Kcnv2. Our data suggested that the Kcvn2 3’ UTR extends 3193-
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3284 bp downstream of the Kcnv2 stop codon. This data is consistent with the 
predicted 3’ UTR in the Ensembl and UCSC genomic databases (GRCm38). 
However, there is a 21 bp poly-A tract in the genomic sequence immediately 
downstream from the location where the longest 3’ RACE product termini align. 
Because the GeneRacer Oligo dT primer used to generate the RACE products 
was designed to bind to the mRNA poly-A tail, the genomic poly-A tract could act 
as an erroneous binding site for the primer. This would result in prematurely 
truncated 3’ RACE products, which would suggest that the 3’UTR is shorter than 
it actually is. For this scenario to occur, the efficiency of either the primer binding 
to or reverse transcription from the erroneous site would have to be greater than 
from the actual poly-A tail. Otherwise, there would also be longer 3’ RACE 
products than the ones that we observed. This was not the case. Nor were there 
longer transcripts identified in the genomic databases. Thus, it is unlikely that the 
poly-A tract influenced our data. Nonetheless, the 3’ RACE data should be 
confirmed by RPA. Future studies will determine whether sequence variation in 
the 3’ UTR contributes to Kcnv2 expression differences between the B6 and SJL 
strains. We also proposed future studies to determine the in vivo effects of 
regulatory sequence variation between the B6 and SJL strains on seizure 
susceptibility in Q54 mice.  
The identification of Kcnv2 regulatory regions provides the foundation for 
the proposed future studies to determine the effects of regulatory sequence 
variation in these regions on Kcnv2 transcription rates and mRNA stability. Taken 
together, these studies will help to elucidate the molecular mechanism of the 
 103 
Kcnv2 modifier effect, advancing our knowledge of how genetic modifiers 
contribute to epilepsy, and potentially revealing novel therapeutic targets for the 
treatment of epilepsy.  
 
Identification of de novo KCNB1 Mutations in Patients with Epileptic 
Encephalopathy 
 
In Chapter IV we describe the identification of three de novo missense 
KCNB1 mutations in three patients with overlapping epileptic encephalopathy 
phenotypes with cognitive and motor dysfunction by whole exome sequencing. 
All three mutations occurred in the pore-forming region of KCNB1 and resulted in 
similar patterns of Kv2.1 dysfunction in a heterologous expression system, 
including both gain-of-function and dominant-negative defects. These defects 
included voltage-independent, non-selective cation currents, and when co-
expressed with wild-type channels, depolarizing shifts in voltage-dependence of 
activation, reduced current density at depolarized voltages, and inward currents 
at more hyperpolarized voltages. Taken together, these defects would be 
predicted to result in a depolarized resting membrane potential and impaired 
membrane repolarization, both of which would contribute to a net increase in 
cellular excitability. The overlapping phenotypic features of the patients and the 
similar functional characteristics exhibited by each of the variants strongly 
suggest that the mutations are pathogenic. The mechanism by which each of the 
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variants contributes to hyperexcitability appears to be similar as each variant 
occurs in the pore-forming region of the channel and results in similar gain-of-
function and dominant negative effects on channel function. The phenotype 
associated with these variants is more severe than the phenotype displayed by 
Kcnb1 homozygous knock out mice, which have increased susceptibility to 
induced seizures but no spontaneous seizure activity [222].  This suggests that 
the phenotypic outcome of KCNB1 mutations is dependent upon the functional 
consequence of the mutation. This is consistent with the pleiotropy exhibited by 
other genes associated with epilepsy [126, 224]. These results implicate KCNB1 
in epileptic encephalopathy and further support the importance of delayed 
rectifier potassium current in the regulation of neuronal excitability. Furthermore, 
these studies emphasize the value of WES for identifying candidate genes in 
patients with idiopathic epilepsies. This approach is more cost effective than the 
current practice of sequencing individual genes or small panels of known 
epilepsy genes and holds a greater potential for discovery of novel epilepsy 
genes. 
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Future Directions 
Effects of Promoter Sequence Variation on Kcnv2 Expression 
As an initial step towards determining whether sequence variation in 
Kcnv2 cis-regulatory regions influences seizure susceptibility by altering steady-
state expression levels, we defined the Kcnv2 promoter and 3’ UTR regions, 
where cis-regulatory elements are likely to be located. The next step is to 
determine whether sequence variation in these regions affects Kcnv2 expression 
levels. Our sequencing identified 11 SNPs (Chapter III), and there are an 
additional 36 imputed SNPs between the B6 and SJL strains in the genomic 
region corresponding to our promoter-luciferase reporter constructs (Fig. 5.1) 
[225]. To determine whether this sequence variation contributes to differences in 
Kcnv2 expression levels, a parallel 5’ deletion series of SJL-derived luciferase 
reporter constructs can be generated, and the resulting luciferase activities can 
be compared to the corresponding B6-derived constructs. If any two 
corresponding B6 and SJL-derived constructs exhibit differences in luciferase 
activity, then the corresponding genomic region is likely to contain sequence 
variation in one or more cis-regulatory elements that influences Kcnv2 
expression.  
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Figure 5.1 Location of Kcnv2 Upstream SNPs  
The location of sequenced and imputed SNPs between the B6 and SJL strains 
relative to the genomic location of promoter construct insert sequences (shown to 
scale). Then number of SNPs contained within each insert is shown below. 
It is possible that multiple regulatory elements with opposing effects on 
Kcnv2 transcription exist within the region being tested. Testing multiple 
constructs within the 5’ deletion series should help to identify these elements, but 
it may be necessary to create additional constructs to evaluate the opposing 
elements independently. Furthermore, our data suggested that Kcnv2 expression 
is actively repressed in the mouse brain-derived Neuro-2a cell line (Chapter III). 
To circumvent this problem and to ensure that all of the relevant trans-regulatory 
elements are expressed, the comparison of B6 and SJL-derived constructs 
should be performed in hippocampal neurons cultured from B6xSJL.F1 mice.  
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Effects of 3’ UTR Sequence Variation on Kcnv2 Expression 
To determine whether sequence variation in the 3’ UTR affects mRNA 
stability, cultured hippocampal neurons from B6xSJL.F1 mice can be treated with 
Actinomycin-D to arrest transcription, and RNA samples can be taken at various 
time points after treatment and used as a template for an allele-specific qRT-
PCR to determine if there are differences in stability between transcripts from the 
B6 and SJL Kcnv2 alleles. If the Kcnv2 mRNA degradation rates vary between 
strains, then the qRT-PCR data should show a more precipitous drop off in 
mRNA levels between time-points for one of the strains, and the ratio of B6:SJL 
Kcnv2 mRNA will deviate from the expected 1:1 ratio. If there are differences in 
Kcnv2 transcription between strains, then mRNA from untreated cells will also 
deviate from the expected 1:1 ratio. In this case, the data from each time point 
will need to be normalized to the ratio from untreated cells.  
In vivo Evaluation of Selected Regulatory Regions 
If the aforementioned in vitro studies suggest that sequence variation in 
the promoter and/or 3’ UTR affects steady-state Kcnv2 expression, then these 
effects can be evaluated in vivo in transient transgenic mice. The B6 BAC clone 
RP24-537C5 contains the Kcnv2 open reading frame plus 63.6 kb upstream of 
the start codon and 37.3 kb downstream of the stop codon. Homologous 
recombination could be used to replace the B6-derived regulatory regions of 
interest with SJL-derived sequence. Additionally, the Kcnv2 open reading frame 
could be replaced with a luciferase reporter gene, allowing transgene-derived 
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transcripts to be easily distinguished from endogenous Kcnv2 transcripts. The 
effects of replacing the B6 sequence with SJL sequence on Kcnv2 expression 
levels could then be monitored using qRT-PCR to compare luciferase transcript 
expression between transient transgenic mice expressing the B6-derived 
transgene with or without SJL-derived sequence in the potential regulatory 
regions of interest. Any regions that exhibit a large effect on Kcnv2 steady-state 
expression when replaced with SJL-derived sequence could be further evaluated 
for effects on seizure susceptibility by using CRISPR technology to generate B6 
Q54 mice with the region of interest replaced by SJL-derived sequence.  
Circadian Regulation of Kcnv2 
There is a well-documented reciprocal interaction between sleep and 
epilepsy [226]. Interestingly, a recent study shows that blood levels of KCNV2 
expression fluctuate with circadian cycles in humans [227]. Evidence that Kcnv2 
may be circadian regulated in mice comes from the presence of a predicted 
Rora2 (a component of the mammalian circadian clock) [228, 229] binding site in 
the promoter region that is conserved in both mouse and human [230] and the 
presence of an miR96 (a light regulated, neurosensory miRNA expressed in hair 
and photreceptor cells) [231] binding site in the 3’ UTR [232, 233]. Intriguingly, 
there is a SNP between the B6 and SJL strains in the predicted miR96 binding 
site. Given that Kcnv2 expression levels contribute to epilepsy susceptibility, it 
may be worthwhile to determine if Kcnv2 expression is circadian regulated in the 
hippocampus of Q54 mice by performing qRT-PCR on hippocampal RNA isolated 
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at multiple time points throughout a 48-hour period. If the data suggests that 
Kcnv2 is circadian regulated, then time of day would need to be controlled for in 
any future experiments in which Kcnv2 expression is a dependent variable. 
Furthermore, if Kcnv2 is circadian regulated, then any cis-regulatory elements 
associated with circadian regulation (e.g. the Rora2 and miR96 binding sites) and 
in which there is sequence variation between B6 and SJL could be prioritized for 
further examination.  
Knock-in Mouse Models of KCNB1 Mutations 
The studies described in Chapter IV showed that mutations in KCNB1 
resulting in both gain-of-function and loss-of-function effects on Kv2.1 mediated 
potassium current are associated with severe epileptic encephalopathy.  Mice 
lacking Kv2.1 (Kcnb1-/-) have reduced thresholds to induced seizures, but they do 
not have spontaneous seizures [222]. This suggests that the phenotypic 
consequences of the gain-of-function and dominant-negative mutations we 
described are inherently different and more severe than a simple loss of Kv2.1-
mediated current by Kcnb1 deletion. To test this hypothesis and to better 
understand how these variants contribute to the epilepsy phenotype, CRISPR 
technology could be used to introduce each of the human mutations described in 
Chapter IV into mice, and the phenotypes of these mice could be compared to 
the phenotype of Kcnb1 knockout mice. If the hypothesis is correct, then the mice 
harboring the human mutations will have a more severe phenotype than the 
knockout mice. The generation of the knock-in mice would also allow us to 
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perform additional experiments to evaluate the effects of the mutations on 
network hyperexcitability, as well as cognitive and motor function.  
Small Molecule Screen for Specific Inhibitors of Kv2.1/Kv8.2 Mediated 
Potassium Current 
Given the importance of Kv2.1/Kv8.2-mediated delayed-rectifier potassium 
current in regulating neuronal excitability and its effect on epilepsy susceptibility, 
a pharmalogical modulator of Kv2.1/Kv8.2 mediated potassium current would be 
a valuable tool. There is a paucity of pharmalogical agents that specifically target 
potassium channels. The anticonvulsant drug ezogabine (retigabine) interacts 
with Kv7.2/Kv7.3 subunit containing potassium channels to activate M-current and 
reduce neuronal excitability, but there are currently no specific inhibitors or 
activators of delayed rectifier potassium current. Such a tool would allow 
investigators to differentiate between Kv2.1/Kv8.2-mediated current and other 
endogenous potassium currents when performing ex vivo electrophysiological 
recordings. These recordings could be used to study the contribution of delayed 
rectifier potassium current to the overall excitability of both excitatory and 
inhibitory neurons in the hippocampus and cortex to better understand the 
physiological consequences of genetic mutations that might alter the current. 
Additionally, this tool could be used to study the effects of altering delayed 
rectifier potassium current on seizure susceptibility in vivo. Furthermore, such a 
molecule could be a candidate for further development and testing as a potential 
therapy for the treatment of epilepsy. Thus, a small molecule screen to discover 
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a specific inhibitor/activator of Kv2.1/Kv8.2 mediated potassium current would be 
a worthwhile endeavor.  
Significance 
This dissertation outlined: the validation of Kcnv2 as a quantitative 
modifier of epilepsy in mice; the identification of KCNV2 variants in pediatric 
epilepsy patients; the determination of Kcnv2 regulatory regions; and the 
identification of KCNB1 mutations in individuals with epileptic encephalopathy. 
Taken together, these studies contribute to our understanding of epilepsy by 
adding KCNV2 and KCNB1 to the growing catalogue of genes associated with 
epilepsy and highlight the importance of delayed-rectifier potassium current in 
governing neuronal excitability. More generally, these studies demonstrate both 
the utility of mouse models for identifying genetic modifiers of epilepsy and the 
potential for genetic modifiers to elucidate underlying disease mechanisms, 
possibly leading to more effective treatment strategies for patients. 
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